



**UNIVERSITI PUTRA MALAYSIA**

***ANTIBACTERIAL, ANTIBIOFILM PROPERTIES AND MECHANISM OF  
ACTION OF PHOSPHANEGOLD(I) THIOLATE COMPLEXES ON  
Staphylococcus aureus STRAINS***

**ANMAR AMEER MOHAMMED SADEQ ALRAWAS**

**FPSK(p) 2022 8**



**ANTIBACTERIAL, ANTIBIOFILM PROPERTIES AND MECHANISM OF  
ACTION OF PHOSPHANE GOLD(I) THIOLATE COMPLEXES ON  
*Staphylococcus aureus* STRAINS**

By

**ANMAR AMEER MOHAMMED SADEQ ALRAWAS**

**Thesis Submitted to the School of Graduate Studies, Universiti Putra Malaysia,  
in Fulfilment of the Requirements for the Degree of Doctor of Philosophy**

**February 2022**

## **COPYRIGHT**

All material contained within the thesis, including without limitation text, logos, icons, photographs, and all other artwork, is copyright material of Universiti Putra Malaysia unless otherwise stated. Use may be made of any material contained within the thesis for non-commercial purposes from the copyright holder. Commercial use of material may only be made with the express, prior, written permission of Universiti Putra Malaysia.

Copyright © Universiti Putra Malaysia



## DEDICATION

With my deepest gratitude and most humble effort, I would like to dedicate this thesis:  
To my dear supervisor **Prof. Ts .Dr. Cheah Yoke Kqueen** who keep supporting me and encourage me throughout my PhD program.

To the soul of my father and sister, who were wishing to see my finishing my PhD before their past away, to my family members for their never ended help, support, and patience during all time.



Abstract of thesis presented to the Senate of Universiti Putra Malaysia in Fulfilment of the Requirement for the degree of Doctor of Philosophy

**ANTIBACTERIAL, ANTIBIOFILM PROPERTIES AND MECHANISM OF ACTION OF PHOSPHANEGOLD(I) THIOLATE COMPLEXES ON *Staphylococcus aureus* STRAINS**

By

**ANMAR AMEER MOHAMMED SADEQ ALRAWAS**

**February 2022**

**Chairman : Professor Ts. Cheah Yoke Kqueen, PhD**  
**Faculty : Medicine and Health Sciences**

With the widespread increase of bacterial resistance to available antibiotics and the lack of resources for the discovery of new classes of antibiotics, the multidrug-resistant *S. aureus* has become a global concern. The methicillin-resistant *Staphylococcus aureus* (MRSA) has been reported as a serious threat in health settings. There is now a strong demand for new antibacterial agents as only a few antibiotics can combat MRSA infections. The notable development of transition metals for medicinal purposes and advanced designs of metal complexes as antibacterial agents have been extended in the research area. These offer good choices as alternative antibacterial agents despite the fact that they have not been explored intensively. Recent *in vitro* studies have highlighted the potential use of gold-based compounds to inhibit the growth of important pathogens, such as MRSA without classifying the mode of action (MOA) or explaining the potential of the growth inhibition mechanism. This research study was aimed at evaluating and investigating the antibacterial activity, anti-biofilm activity, synergistic interaction, and classification of the mode of action of the novel 3F2 phosphanegold(I) thiolate compound. Preliminary screening using the disc diffusion method showed that the novel 3F2 gold compound possesses a noticeable antibacterial activity against MRSA strains with an average inhibition zone ranging between 8 mm to 12 mm. The minimum inhibitory concentration (MIC) and the minimum bactericidal concentration (MBC) of the 3F2 gold compound against MRSA strains was in range of 4 µg/mL to 8 µg/mL. Moreover, the dose-dependent 3F2 gold compound exhibited bactericidal activity against MRSA during the first twelve hours. The interaction of the novel 3F2 compound in combination with ciprofloxacin showed a partially synergistic activity with FICI = 0.53 using the checkerboard method. Also, the 3F2 gold compound showed an anti-biofilm activity, whereby cell viability was reduced by more than 50 percent. InCelligence technology and the CLSM microscopic results proved the inhibition/eradication of *S. aureus* biofilm formation with MIBC in the range of 3.125 µg/mL to 12.5 µg/mL. Furthermore, the predicted mode of action (MOA) of the 3F2 gold compound was classified based on a data analysis of the phenotypic microarray.

The Pearson correlation and clustering analysis showed that the mode of action was similar to that of vancomycin in targeting the MRSA cell wall. However, the TEM and RT-PCR results supported the predicted mode of action. Finally, all the findings showed promising antibacterial activity by the new 3F2 gold compound, with a unique potential MOA against MRSA. Overall, the thesis results are beneficial for both the development of antibacterial agents and gaining an understanding of the mechanism of action to minimize the multi-drug resistance, and to develop new methods of identifying and classifying the mode of action of new antibacterial agents



Abstrak tesis yang dikemukakan kepada Senat Universiti Putra Malaysia sebagai memenuhi keperluan untuk ijazah Doktor Falsafah

**AKTIVITI ANTIBAKTERIA, ANTIBIOFILM DAN MEKANISME  
TINDAKAN LOGAM PERALIHAN *PHOSPHANGOLD(I) THIOLATE*  
TERHADAP *Staphylococcus aureus***

Oleh

**ANMAR AMEER MOHAMMED SADEQ ALRAWAS**

**Februari 2022**

**Pengerusi : Profesor Ts. Cheah Yoke Kqueen, PhD**  
**Fakulti : Perubatan dan Sains Kesihatan**

Peningkatan tahap kerintangan bakteria terhadap antibiotik yang sedia ada secara meluas dan kekurangan sumber dalam penemuan kelas antibiotik baru telah menyebabkan *S.aureus* yang rintang pelbagai antibiotik menjadi kebimbangan global. *Staphylococcus aureus* (MRSA) yang rintang metisilin telah dilaporkan sebagai ancaman serius terhadap kesihatan. Kini, terdapat permintaan yang tinggi untuk penemuan agen antibakteria yang baru kerana hanya beberapa antibiotik boleh menangani jangkitan MRSA. Perkembangan penting logam peralihan untuk tujuan perubatan dan rekaan unggul kompleks logam sebagai agen antibakteria telah diperluaskan dalam bidang penyelidikan. Ini menyebabkan ia adalah pilihan yang baik sebagai agen antibakteria alternatif walaupun hakikatnya ia belum diterokai secara intensif. Kajian in vitro terbaru menekankan potensi penggunaan sebatian berasaskan emas untuk menghalang pertumbuhan patogen yang penting, seperti MRSA tanpa mengklasifikasikan mod tindakan (MOA) atau menjelaskan potensi mekanisme perencatan pertumbuhan. Oleh itu, kajian ini bertujuan untuk menilai dan menyelidik aktiviti antibakteria, anti-biofilem, interaksi sinergistik, dan klasifikasi mod tindakan sebatian novel *phosphangold (I) thiolate* 3F2. Saringan awal menggunakan kaedah penyebaran cakera menunjukkan bahawa sebatian novel emas 3F2 mempunyai aktiviti antibakteria yang ketara terhadap strain MRSA dengan zon perencatan purata di antara 8 mm hingga 12 mm. Kepekatan perencatan minimum (MIC) dan kepekatan bakteria minimum (MBC) sebatian emas 3F2 terhadap strain MRSA adalah di antara 4 µg/mL hingga 8 µg/mL. Selain itu, sebatian emas 3F2 yang bergantung kepada dos menunjukkan aktiviti bakteria terhadap MRSA dalam tempoh dua belas jam pertama. Interaksi sebatian novel 3F2 dengan kombinasi ciprofloxacin menunjukkan aktiviti separa sinergistik dengan FICI = 0.53 menggunakan kaedah papan dam. Selain itu, sebatian emas 3F2 menunjukkan aktiviti anti-biofilem, di mana kehidupan sel berkurangan lebih daripada 50 peratus. Teknologi InCelligence dan keputusan mikroskopik CLSM membuktikan perencatan/pembasmian pembentukan biofilem *S. aureus* dengan julat MIBC sebanyak 3.125 µg/mL hingga 12.5 µg/mL. Tambahan pula, mod tindakan (MOA) yang diramalkan bagi sebatian emas 3F2

dikelaskan berdasarkan analisis data mikrotatasusunan fenotip. Analisis korelasi dan pengelompokan Pearson menunjukkan bahawa mod tindakan adalah serupa dengan vankomisin dalam menyasarkan dinding sel MRSA. Walau bagaimanapun, keputusan TEM dan RT-PCR menyokong mod tindakan yang diramalkan. Akhir sekali, semua penemuan menunjukkan aktiviti antibakteria oleh sebatian emas 3F2 dengan potensi MOA yang unik terhadap MRSA. Secara keseluruhannya, hasil tesis ini adalah bermanfaat untuk pembangunan agen antibakteria dan pemahaman tentang mekanisme tindakan untuk meminimumkan rintangan pelbagai antibiotik dan untuk membangunkan kaedah baru untuk mengenal pasti dan mengklasifikasikan mod tindakan agen antibakteria baru.





## ACKNOWLEDGEMENTS

I would like to appreciate supervisory committee chaired by Prof. Ts.Dr. Cheah Yoke Kqueen for their continuous support and monitoring my experimental work flow of this thesis, imparting priceless knowledge and skills and helping me working on both independently and dependently which polish up my lab skills and building up my confidence in handling research and scientific work here. Moreover, I would like to extend my special thanks to Prof. Christina Bourne from Oklahoma University for her endless support and guides in term of Mode of action data analysis. I would also like to express my special thanks to all my lab mates and staff in the laboratories of faculty of Medicine and Health Sciences- UPM where all provide a happy and friendly working atmosphere, support and share knowledge.

Finally, I would like to extend very special gratitude to my family members especially my mother who always give their moral and emotion support and being patient with me during all my study time.

This thesis was submitted to the Senate of Universiti Putra Malaysia and has been accepted as fulfilment of the requirement for the degree of Doctor of Philosophy. The members of the Supervisory Committee were as follows:

**Cheah Yoke Kqueen, PhD**

Professor, Ts  
Faculty of Medicine and Health Sciences  
Universiti Putra Malaysia  
(Chairman)

**Tengku Zetty Maztura binti Tengku Jamaluddin, MBChB, PhD**

Medical Lecturer  
Faculty of Medicine and Health Sciences  
Universiti Putra Malaysia  
(Member)

**Nur Fariesha binti Md Hashim, PhD**

Senior Lecturer  
Faculty of Medicine and Health Sciences  
Universiti Putra Malaysia  
(Member)

---

**ZALILAH MOHD SHARIFF, PhD**

Professor and Dean  
School of Graduate Studies  
Universiti Putra Malaysia

Date: 9 June 2022

## Declaration by Members of Supervisory Committee

This is to confirm that:

- the research conducted and the writing of this thesis was under our supervision;
- supervision responsibilities as stated in the Universiti Putra Malaysia (Graduate Studies) Rules 2003 (Revision 2012-2013) are adhered to.

Signature: \_\_\_\_\_  
Name of Chairman  
of Supervisory  
Committee: Professor Ts. Dr. Cheah Yoke Kqueen

Signature: \_\_\_\_\_  
Name of Member  
of Supervisory  
Committee: Dr. Tengku Zetty Maztura binti Tengku Jamaluddin

Signature: \_\_\_\_\_  
Name of Member  
of Supervisory  
Committee: Dr. Nur Fariesha binti Md Hashim

## TABLE OF CONTENTS

	<b>Page</b>
<b>ABSTRACT</b>	i
<b>ABSTRAK</b>	iii
<b>ACKNOWLEDGEMENTS</b>	v
<b>APPROVAL</b>	vi
<b>DECLARATION</b>	viii
<b>LIST OF TABLES</b>	xiv
<b>LIST OF FIGURES</b>	xvi
<b>LIST OF APPENDICES</b>	xix
<b>LIST OF ABBREVIATIONS</b>	xx
<b>CHAPTER</b>	
<b>1 INTRODUCTION</b>	<b>1</b>
1.1 Background	1
1.2 Problem Statement	3
1.3 Justification for the Study	3
1.4 Hypothesis	4
1.5 Objectives	4
1.5.1 General Objective	4
1.5.2 Specific objectives	5
1.6 Conceptual framework	6
<b>2 LITERATURE REVIEW</b>	<b>7</b>
2.1 Staphylococcus aureus Infection	7
2.2 Staphylococcus aureus Biofilm	8
2.3 Resistance to Antibiotics	10
2.4 Mode of Action of Antibiotics	11
2.5 Metal Based Drugs as Antimicrobial	14
2.6 Gold compound as Antibacterial agents	17
2.7 Approaches in Understanding the MOA of Antimicrobial Agents	23
2.7.1 Proteomic approach	23
2.7.2 Microscopic approach	23
2.7.3 Genomic Based methods	24
2.7.4 Computation inference methods	25
2.7.5 Phenotypic and Metabolomics base assay	25
2.8 Phenotype Microarray	26
2.9 Combination Effects of Antimicrobials Agents	28
2.9.1 Checkerboard Method	29

<b>3</b>	<b>IN VITRO EVALUATION OF ANTIBACTERIAL ACTIVITY OF SEVERAL GOLD (I) N-HETEROCYCLIC CARBENE (NHC) COMPLEXES AGAINST GRAM NEGATIVE AND GRAM POSITIVE PATHOGENS</b>	31
3.1	Introduction	31
3.2	Methodology	33
3.2.1	Gold Compounds	33
3.2.2	Preparation of Bacterial Pathogens	33
3.2.3	Disc Diffusion Method	35
3.2.4	Determination of MIC and MBC	35
3.2.5	Time Killing Assay	36
3.3	Results	36
3.3.1	Preliminary Screening of Gold Compound Complex	36
3.3.2	Anti- <i>Staphylococcus aureus</i> activity of gold compound complexes 3F3 and 3F2	39
3.3.3	Determination of MIC and MBC	40
3.3.4	Time Killing Curve	43
3.4	Discussion	48
3.5	Conclusion	52
<b>4</b>	<b>EVALUATION OF SYNERGISTIC ANTI-STAPHYLOCOCCUS AURUES ACTIVITY OF PHOSPHANEGOLD(I) THIOLATE COMPOUND WITH STANDARD ANTIBIOTICS</b>	53
4.1	Introduction	53
4.2	Methodology	54
4.2.1	Checkerboard Method	54
4.2.2	Experimental Steps	55
4.2.3	Antibiotic Solution preparation	55
4.2.4	Preparation of 3F2 Gold compound Working Solution.	56
4.2.5	Preparation of Inoculating <i>Staphylococcus aureus</i>	57
4.2.6	Combeneft Software	57
4.2.7	Time killing Assay of 3F2 in Combination with Ciprofloxacin	57
4.3	Results	57
4.4	Discussion	64
4.5	Conclusion	66
<b>5</b>	<b>THE EFFECT OF PHOSPHANEGOLD (I) THIOLATE COMPOUND ON <i>S. aureus</i> BIOFILM FORMATION</b>	67
5.1	Introduction	67
5.2	Methodology	69
5.2.1	Biofilm Formation Assay	69
5.2.2	Anti-Biofilm formation Activity of 3F2 Gold Complex	69
5.2.3	Biofilm Eradication/Removal activity of 3F2 Gold Complex	70

5.2.4	Visualizing the Effect of 3F2 Gold Complex on the Biomass of MRSA 43300 Biofilm by Air-Liquid Interface (ALI) Assay	71
5.2.5	Visualizing the Effect of 3F2 Gold Complex on the <i>S. aureus</i> Biofilm using Chamber slide and Inverted Florescent Microscopy	71
5.2.6	Effect of 3F2 Phosphanegold (I) Thiolate Compound on the Thickness of <i>S. aureus</i> Biofilm	72
5.2.7	Real Time Monitoring of Formation and Removal of <i>S. aureus</i> Biofilm with Treatment of Phosphanegold (I) Thiolate compound	72
5.2.8	Monitoring of Extracellular Matrix mediating Biofilm Development in MRSA Biofilm after Treatment with 3F2 Gold Compound	73
5.2.9	Expression of the Biofilm-Associated Genes in Methicillin-Resistant <i>Staphylococcus aureus</i>	73
5.2.10	Statistical analysis	75
5.3	Results	75
5.3.1	Determination of Biofilm formation	75
5.3.2	Determination of MBIC and MBEC of Phosphangold(I)thiolate (3F2) Compound	76
5.3.3	Visualizing the Effect of 3F2 Gold Complex on the Biomass of <i>S. aureus</i> Biofilm using Inverted Microscope	80
5.3.4	Effect of 3F2 Phosphanegold (I) Thiolate Compound on the Thickness of the <i>S. aureus</i> Biofilm	82
5.3.5	RTCA of <i>S. aureus</i> Biofilm Inhibition/Removal and Extracellular Matrix Mediating Biofilm	85
5.3.6	Impact of 3F2 Gold Compound on Biofilm-association Genes Expression	87
5.4	Discussion	89
5.5	Conclusion	94
<b>6</b>	<b>CLASSIFYING, PREDICTION 3F2 GOLD COMPOUND MODE OF ACTION (MOA) IN RESPONSE TO METHICILLIN – RESISTANT <i>Staphylococcus aureus</i> MOLECULAR TARGET</b>	<b>96</b>
6.1	Introduction	96
6.2	Methodology	97
6.2.1	3F2 Gold Compound Preparation	97
6.2.2	Optimization of PM Experiment	97
6.2.3	Phenotype Microarray Experimental Steps	98
6.2.4	Calculation of Phenotype Microarray Data	99
6.2.5	Visualization of the Effect of 3F2 Gold Compound on Cell Membrane Using Transmission Electron Microscope	100
6.2.6	Quantitative of Gene Expression of Related Cell Membrane Biosynthesis Genes	100

	6.2.7	Statistical analysis	101
6.3		Results	102
	6.3.1	PM for the Prediction of the Mode of Action of 3F2 Gold Complex	102
	6.3.2	Impact OF 3F2 Gold Compound on Cell Membrane Using TEM	106
	6.3.3	Expression of Related Cell Membrane Biosynthesis Genes	106
6.4		Discussion	108
6.5		Conclusion	113
<b>7</b>		<b>SUMMARY, GENERAL CONCLUSION AND RECOMMENDATION FOR FUTURE RESEARCHES</b>	<b>114</b>
	7.1	Summary and General Conclusion	114
	7.2	Recommendation For Future Work	117
		<b>REFERENCES</b>	<b>118</b>
		<b>APPENDICES</b>	<b>140</b>
		<b>BIODATA OF STUDENT</b>	<b>148</b>
		<b>LIST OF PUBLICATIONS</b>	<b>149</b>

## LIST OF TABLES

Table	Page	
2.1	Some of metal complexes used as antimicrobial agents against bacterial pathogens	20
2.2	Most common methods used to study combination of antimicrobial agents	29
3.1	Chemical formula, Molecular weight and preferable solvent for the investigated Phosphanegold(I) Thiolate	33
3.2	Bacterial pathogen strains of the preliminary screening of Phosphanegold (I) Thiolate antibacterial activity	34
3.3	List of <i>Staphylococcus aureus</i> reference strains	34
3.4	Preliminary screening of gold compound complexes against important pathogens.	38
3.5	Antibacterial activity measured by zone of inhibition of gold compounds 3F3, 3F2 and standard antibiotics	40
3.6	MIC (MBC) and MIC/MBC ratio of 3F2, 3F3 and standard antibiotics against <i>S. aureus</i> reference strains	42
3.7	MIC distribution of 3F2 and 3F3 against <i>S. aureus</i> strains	43
4.1	Combination of 3F2 and ciprofloxacin and fractional inhibitory concentration index	58
4.2	Combination of 3F2 and ampicillin and Fractional inhibitory concentration index	60
5.1	Sequences of primers tested biofilm associated genes for real-time qRT-PCR analyses	74
5.2	Quantification of biofilms formed by methicillin-resistant <i>S. aureus</i> isolates using microtiter plate assay	75
5.3	Comparison of MBIC average (standard deviation) between 3F2 Gold Complex and Vancomycin	77
5.4	The relative gene expression results of biofilm association genes examined in MRSA(ATCC43300)	89
6.1	Recipe for 1x PM inoculating fluids from stock solutions	98



6.2	PM Recipe for 1x PM inoculating fluids from stock solutions	98
6.3	Cell wall biosynthesis associated genes and its primers design sequence used in this chapter	101
6.4	The relative gene expression results of genes involved in cell wall biosynthesis examined in MRSA(ATCC43300)	108



## LIST OF FIGURES

Figure		Page
1.1	Conceptual framework illustrates concept map of the antibacterial activity and mode of action of phosphanegold(I) thiolate complexes	6
2.1	Model of <i>S. aureus</i> biofilm development. described in five stages (Moormeier and Bayles, 2017)	9
2.2	Scheme illustrated the mechanisms of antimicrobial resistance in <i>S. aureus</i> .	11
2.3	Schematic representation of the peptidoglycan synthesis and targets of cell wall active antibiotics in <i>S. aureus</i>	13
2.4	Metal based drug usage in different aspects in medicine	14
2.5	Illustration of how cell respiration associated with phenotypes	27
2.6	Example of Isobologram illustrating the synergism and antagonism of two antibiotic combination (Schwalbe et al., 2007a)	30
3.1	Antimicrobial susceptibility test (disc diffusion method) MRSA ATCC43300.	37
3.2	Antimicrobial susceptibility test (disc diffusion method) MSSA ATCC25923	38
3.3	Time killing assay of 3F2 Gold complex against MRSA JCSC990	44
3.4	Time killing assay of 3F2 Gold complex against MRSA JCSC9901	45
3.5	Time killing assay of 3F2 Gold complex against MRSA JCSC9902	45
3.6	Time killing assay of 3F2 Gold complex against MRSA JCSC9890	46
3.7	Time killing assay of 3F2 Gold complex against MRSA JCSC9889	46
3.8	Time killing assay of 3F2 Gold complex against MRSA JCSC9885	47
3.9	Time killing assay of 3F2 Gold complex against MRSA JCSC9884	47
3.10	Time killing assay of 3F2 Gold complex against MRSA ATCC4330	48
4.1	An example of broth micro dilution Checkerboard method for Gold compound 3F2 in combination with Ciprofloxacin	56

4.2	Scheme illustrates the panel of drugs interaction between 3F2 gold compound and ciprofloxacin	59
4.3	Scheme illustrates the panel of drugs interaction between 3F2 gold complex and ampicillin	60
4.4	Isobologram illustrates the FICI profile of 3F2 Gold compound in combination with ciprofloxacin	61
4.5	Isobologram illustrates the FICI profile of 3F2 Gold compound in combination with Ampicillin	61
4.6	Time killing curve for synergistic combination activity between 3F2 Gold complex and ciprofloxacin under fixed condition for 24 hours exposure.	62
4.7	Synergy score distribution of drug combination between 3F2 Gold compound and ciprofloxacin	63
5.1	Anti-biofilm activity of 3F2 gold compound (blue columns) in comparison to standard antibiotic vancomycin (orange columns) against six different of MRSA strains	78
5.2	Biofilm eradication activity of 3F2 gold compound against different MRSA strains	79
5.3	Inverted micrographs taken at the air-liquid interface line of MRSA (ATCC43300) biofilm	81
5.4	Inhibition of Biofilm detected by Florescent Microscope	82
5.5	Random views of two days old MRSA (ATCC43300) biofilm	83
5.6	Random views of two day's old, treated MRSA (ATCC43300) biofilm	84
5.7	Representative graph illustrates the dead/live cell ratio	85
5.8	RTCA analysis of Inhibition/Removal of 4 hours old MRSA (ATCC43300) biofilm treated with 3F2 Gold Compound	86
5.9	Proteinase K treated <i>S. aureus</i> Biofilm. Dispersal of MRSA biofilm treated with 3F2 gold compound	87
5.10	Gene expression profiling of Biofilm association genes examined in MRSA (ATCC 43300)	88
6.1	Pearson correlation values between antibiotics and 3F2 gold compound	103

6.2	Dendrogram of Mode of Action (MOA) clusters derived from Phenotype Microarray	105
6.3	Transmission Electron Microscope images of MRSA ATCC 43300	106
6.4	Gene expression profiling of some genes involved in MRSA (ATCC 43300) peptidoglycan precursors biosynthesis	107
6.5	Schematic diagram of the cytoplasmic and membrane related steps of peptidoglycan biosynthesis in <i>S. aureus</i>	112



## LIST OF APPENDICES

Appendix		Page
1	Checkerboard experimental steps as described by (Schwalbe et al, 2007)	140
2	An example of broth micro dilution Checkerboard method for Gold compound 3F2 in combination with ampicillin, chloramphenicol and vancomycin. Reproduce from (Schwalbe et al, 2007)	142
3	Scheme illustrates the panel of drug interaction between 3F2 gold complex in combination with Ampicillin, Chloramphenicol and Vancomycin. Green indicates no bacterial growth; Red indicates bacterial growth; BC: Blank (negative control) and GC: Growth control	143
4	Composition and Preparation of 12x PM Additive Solutions. Prepare all 120x stock solutions, filter sterilize, and store at 4 °C. Combine ingredients and Q.S. to 100 ml. Store at 4 °C. (Adapted from Biolog PM Procedure manual).	144
5	Example of the generated 3D shaped isobologram within Excel as 3D contour plots. The converted average heights value to growth percentage were used to construct the Isobologram for each PM plate	145
6	Known MOA antibiotics used in this PM analysis. Abbreviations are as specified in CLSI documents (CLSI 2010)	146
7	PM 1-2 control plates using the same amount of the PM solutions based on PM procedure of Gram-positive bacterial protocol with ½ MIC value showing no interface of the Biolog media and additives reagents with 3F2 phosphanegold(I)thiolate compound	147

## LIST OF ABBREVIATIONS

AIP	Auto-inducing peptide
ALI assay	Air-liquid interface assay
AO/ PI	Acridine Orange / propidium Iodide
ATCC	American type culture collection
CLMS	Confocal leaser scanning microscopy
CLSI	Clinical laboratory standards institute
CUF	Colony forming unit
CWA	Cell wall anchored
DHFR	Dihydrofolate reductase
DMSO	Dimethylsulphoxide
ECM	Extra cellular matrix
eDNA	Extracellular DNA
FAO	The Food and Agriculture Organization
FICI	Fractional inhibitory concentration index
HSA	Highest single agent
INT	Iodonitrotetrazolium violet
LCMS	Liquid chromatography mass spectrometry
MBC	Minimum bactericidal concentration
MDR	Multi-drug resistance
MHB	Muller-hinton broth
MIC	Minimum inhibitory concentration
MOA	Mode of Action / Mechanism of Action
MRSA	Methicillin- resistant <i>Staphylococcus arues</i>

MSCRAMMs	Microbial surface components recognizing adhesive matrix molecules
NA	Nutrient agar
NAM / NAG	Acetylmuramic acid / N-acetylglucosamine
NMR	Magnetic resonance
O.D	Optical density
OIE	World Organization for Animal Health
PBS	Phosphate buffered saline
PG	Peptidoglycan
PIA	Polysaccharide intercellular adhesion
PM	Phenotype microarray
PSM	Phenol soluble modulins
RT_PCR	Real-time Polymerase Chain Reaction
RTCA	Real-time cell analysis
SCC <sub>mec</sub>	Staphylococcal cassette chromosome <i>mec</i>
SD	Standard deviation
SEM	Scanning electron microscope
SSS	Scalded-skin syndrome
ST	Sexual transmitted diseases
TEM	Transmission electron microscope
TSA / TSB	Tryptic soya Agar / Broth
TSS	Toxic shock syndrom
ViSA	Vancomycin intermediate <i>Staphylococcus aureus</i>
WGS	Whole genome sequencing
WHO	World health organization

WTA	Wall teichoic acid
°C	Degree Centigrade / Celsius
µg/mL	Microgram per Millilitre
3F2	Tricyclohexylphosphane-gold(I)-O-methyl-N-(3-fluorophenyl)thiocarbamate
3F3	Bis(diphenylphosphino)ferrocene-di gold(I)- O-methyl N-(3-fluorophenyl)-thiocarbamate
3FL	O-methyl-N-(3-fluorophenyl)-thiocarbamate





# CHAPTER 1

## INTRODUCTION

### 1.1 Background

Over the years, the World Health Organization (WHO), the Food and Agriculture Organization (FAO) and the World Organization for Animal Health (OIE) have become increasingly concerned about the serious health problems posed globally to humans and animals by multidrug-resistant (MDR) pathogenic bacteria. However, infectious diseases remain one of the main causes of many illnesses and deaths around the world. Microbes, such as multidrug-resistant bacteria, are the major cause of severe fever, sepsis, diarrhoea, respiratory diseases, skin infections, sexually transmitted diseases (STD) and many others, and very serious actions are required to stop or reduce the threat of these MDR pathogens and to save the lives of many people. The advance of phenotypic resistance in microorganisms, specifically MDR bacteria, to current antibiotics and the emergence of new infectious diseases have become global issues in the twenty-first century, thereby making it essential that novel, safe and effective antimicrobial agents be discovered (Rojas et al., 2003)

The Gram-positive bacterium, *S. aureus*, is one of the main pathogenic bacteria that is emerging increasingly due to the rapid development of resistance against a series of first, second and third line antibiotics that are usually used to treat infectious diseases caused by the *S. aureus* (Harris et al., 2002; Theuretzbacher, 2011).

The methicillin-resistant *Staphylococcus aureus* (MRSA) remains one of the most difficult infections to treat due to its ability to develop resistance against available antibiotics, despite the introduction of new derivatives, and the abuse of these antibiotics (Rodvold and McConeghy, 2014). Many of these antibiotics and their derivatives are linked to dose limitations, development of resistance, and expensive costs. This will be discussed in detail in Chapter 2. In addition, over the last two decades, there has been a noticeable increase in the number of cases of vancomycin intermediate-resistant *Staphylococcus aureus* (ViSA) and vancomycin-resistant *Staphylococcus aureus* (VRSA) around the world, and the resistance mechanisms of the aforementioned strains are quite different, thus, making it difficult to treat them with the same antibiotics (Fridkin, 2001; Hiramatsu et al., 2014). Vancomycin is still the drug of choice for the treatment of MRSA infections, despite the fact that resistance to this antibiotic has been increasing noticeably (Bérdy, 2012; Tegos and Hamblin, 2005; McGuinness et al., 2017). Thus, the demand for active drug discovery approaches for the development of new antimicrobial agents is being highlighted. Moreover, infectious diseases associated with the *Staphylococcus aureus* biofilm are another challenge as it is well known that the biofilm population is physiologically different from its planktonic counterpart, and is better able to persist in the infected host, even under harsh environmental stress. As a result, the resistance mechanism of bacterial cell biofilms is different from that of planktonic cells (Petrelli et al., 2017; Pozo and Patel, 2007).

The ability of the *S. aureus*, specifically the MRSA, to form biofilms is one of the main factors for the virulence of nosocomial infections. Moreover, infections caused by *S. aureus* strains that possess the ability to form biofilms are more difficult to treat with existing antibiotics as these antibiotics have not been specifically designed to treat biofilm infections (Agarwal and Jain, 2012; Costerton, 2012; Lynch and Abbanat, 2010). Hence, there is now a strong demand for the discovery, design or synthesis of new antibacterial agents to treat biofilm-forming bacteria.

In addition to the remarkable therapeutic success of some existing antibacterial agents, metal-based antimicrobial agents have shown promising results in the laboratory. Metallo drugs have been used for a long time prior to the discovery of organic antibiotics. Since then, there has been a general decline in the use of metal-based drugs, particularly antibacterial compounds, with the exception of silver compounds (Bharti and Singh, 2009; Hobman and Crossman, 2015). The use of metal-based antibacterial agents is one of the strategies adapted by many researchers to combat the challenges of bacterial resistance to antibiotics worldwide. Metal-based agents *in vitro*, in the form of complexes or salt complexes, in particular, have been able to combat bacterial resistance (Hobman and Crossman, 2015).

The gold element (Au) and its complexes have also been used in medicine throughout civilization until the present day. A gold complex was clinically used as treatment for rheumatic disease. Later on, in the middle of the 20th century, gold complexes were screened and evaluated for their potential use as antibacterial agents (Glisic and Djuran, 2014). Interest in the potential antibacterial properties of gold(I) and gold(III) complexes was sparked by Robert Koch, who used potassium dicyanoaurate(I) to treat tuberculosis, a disease caused by the *Mycobacterium tuberculosis* (Tiekink, 2002). Later on, a great number of gold(I) and gold(III) complexes were used against a wide spectrum of bacterial pathogens, although the majority of the studies were carried out on gold(I) compounds, perhaps because of their greater stability compared to gold(III) compounds (Glisic and Djuran, 2014).

Notwithstanding that metal-based antibacterial agents have been shown to be effective against a wide range of Gram-positive and Gram-negative pathogens, some studies have revealed that these pathogens have started to develop a resistance to metal ions, especially towards silver ions, but this is not the case with gold-based antibacterial agents (Hobman and Crossman, 2015). This resistance to metal ions is probably due to a lack of knowledge and understanding on the mechanism of action of metal-based antibacterial agents.

There is a rising clinical demand for new antibacterial agents as the therapeutic efficacy of current antibiotics against Gram-positive cocci is very limited due to the emergence of MDR *S. aureus* strains, such as MRSA and VRSA (Fricker, 1996). Hence, the aim of this study was to investigate and evaluate *in vitro* the antibacterial activity of

phosphanegold(I) thiolate complexes against a wide range of pathogens, including *S. aureus* strains, as well as to investigate the ability of phosphanegold(I) thiolate to inhibit or remove the *S. aureus* biofilm. This study was also aimed at investigating and predicting the mechanism of action of phosphanegold(I) thiolate against *S. aureus* strains.

## 1.2 Problem Statement

Bacterial infections caused by pathogens, such as the multidrug-resistant *S. aureus*, are still a global concern, and one of the main reasons for the increasing morbidity and mortality rates is bacterial resistance to current antibiotics, which is growing dramatically and threatening public health globally. Besides that, for many years now, no new classes of antimicrobial agents have been introduced into the market, and the rate of discovery of new antimicrobial agents has been very low and insufficient to counter the challenging growth of antibacterial resistance. The *S. aureus* has developed a resistance against a series of first, second and third-line antibiotics, including beta-lactam and glycopeptide antibiotics, to be classified as methicillin-resistant *Staphylococcus aureus* (MRSA) and vancomycin-resistant *Staphylococcus aureus* (VRSA), respectively. Therefore, this pathogen is a risk factor for hospital-acquired and community-acquired infections. In addition, diseases associated with the *S. aureus* biofilm have displayed a greater resistance to antibiotics and combinations of different antibacterial agents. In contrast to organic antibacterial agents, less attention has been paid to inorganic antibacterial agents, such as metal-based drugs. Many attempts have been made to overcome the issue of bacterial resistance by the *S. aureus*. Researchers have investigated the antibacterial effectiveness of metal and metal-based medicines *in vitro* against several strains of the *S. aureus*. Silver, copper, lead, platinum, gold, and other metal complexes have been reported to have antibacterial properties. However, bacteria, including the *S. aureus*, may develop a resistance against some of these metal compounds. Moreover, lack of knowledge on the mode of action or mechanism of action of metal compounds has limited their usage recently as antibacterial agents. Indeed, a few gold-based drugs, such as gold(I) with phosphine ligand or N-heterocyclic carbene ligand complexes, have been reported to possess potential antibacterial properties against the *S. aureus* without having developed any resistance as yet. However, the mechanism of action of these gold compounds on bacterial cells is still not fully understood. Thus, a study that can provide enough information about the mechanism of action of gold-based antibacterial agents may help to reduce the bacterial resistance of the *S. aureus*.

## 1.3 Justification for the Study

Metal-based drugs are reported to have multiple uses in health settings due to their antimicrobial, anticancer, anti-inflammatory, and many other properties. It has been disclosed in the literature that gold-based drugs are purported to be promising antibacterial agents against critical human pathogens, including the *S. aureus*.

In this study, the novel phosphanegold(I) thiolate compounds known as the 3F series (containing 3F2, 3F3, 3F4, 3F5, 3F6, and 3FL) were investigated for their antibacterial and antibiofilm properties individually or in combination with other standard antibiotics against *S. aureus* strains. Also, the mechanism of action of the phosphanegold(I) thiolate compounds was predicted and determined against the methicillin-resistant *Staphylococcus aureus* using new Phenotype MicroArray (PM) technology. The outcomes of this study may contribute richly to the further development of antibacterial agents derived from metal-based drugs. Moreover, the prediction of the mode of action using PM technology may open the door to a better understanding of the mechanism of action of metal-based drugs and, therefore, lead to the designing of more potent gold-based compounds as antibacterial agents.

#### **1.4 Hypothesis**

Novel phosphanegold(I) thiolate compounds under the 3F series (3F2, 3F3, 3F4, 3F5, 3F6, and 3FL), either individually or in combination, have a unique mechanism of action and potent antibacterial activity against *S. aureus* strains. Thus, an investigation into the antibacterial activity of the abovementioned phosphanegold(I) thiolate compounds was carried out *in vitro*, and subsequently, the anti-biofilm ability of the compounds against the *S. aureus* biofilm-producing strains and the synergistic interaction of the most potent phosphanegold(I) thiolate compound were investigated. Furthermore, the mechanism of action of the best phosphanegold(I) thiolate compound among the above six compounds was predicted and determined using Phenotype MicroArray technology.

#### **1.5 Objectives**

##### **1.5.1 General Objective**

To investigate and characterize the biological properties of phosphanegold(I) thiolate complexes (3F series) as potential antibacterial agents against *S. aureus* strains, and to predict the general mechanism of action of the best phosphanegold(I) thiolate complex among the 3F series.

To achieve the above general objective, the following specific objectives were set.

### 1.5.2 Specific objectives

- 1- To conduct a preliminary screening and evaluation of the antibacterial properties of phosphanegold(I) thiolate complexes (3F series) *in vitro* against Gram-negative and Gram-positive pathogens.
- 2- To investigate the synergistic activity of the 3F2 (phosphanegold(I) thiolate) complex in combination with antibiotics with a known mode of action against the methicillin-resistant *Staphylococcus aureus* (ATCC43300).
- 3- To investigate the ability of the 3F2 (phosphanegold(I) thiolate) complex to inhibit/eradicate the *Staphylococcus aureus* (ATCC43300) biofilm.
- 4- To predict the mechanism of action (MOA) of the 3F2 phosphanegold(I) thiolate complex by studying the phenotypic profile of the methicillin-resistant *Staphylococcus aureus* (ATCC43300).

## 1.6 Conceptual framework




Figure 1.1 : Conceptual framework illustrates concept map of the antibacterial activity and mode of action of phosphane-gold(I) thiolate complexes. Four working chapters are indicated by curly brackets in this thesis



## REFERENCES

- Abdulmir., A. S., Jassim., S. A. A., Hafidh., R. R., and Bakar., F. A. (2015). The potential of bacteriophage cocktail in eliminating Methicillin-resistant *Staphylococcus aureus* biofilms in terms of different extracellular matrices expressed by PIA, *ciaA-D* and *FnBPA* genes. *Annals of Clinical Microbiology and Antimicrobials*. <https://doi.org/10.1186/s12941-015-0106-0>
- Acar., J. F. (2000). Antibiotic synergy and antagonism. *Medical Clinics of North America*, 84(6), 1391–1406. [https://doi.org/10.1016/S0025-7125\(05\)70294-7](https://doi.org/10.1016/S0025-7125(05)70294-7)
- Agarwal., A., and Jain., A. (2012). Association between drug resistance & production of biofilm in staphylococci. *Indian Journal of Medical Research*, 135(4), 562–564.
- Agarwal., A., and Jain., A. (2013). Glucose & sodium chloride induced biofilm production & *ica* operon in clinical isolates of staphylococci, (August), 262–266.
- Ala'Aldeen., D. a. a., and Hiramatsu., K. (2004). *Staphylococcus aureus: molecular and clinical aspects*. Retrieved from <http://books.google.com/books?id=2NNnA98Pbi8C&pgis=1>
- Alhanout., K., Malesinki., S., Vidal., N., Peyrot., V., Rolain., J. M., and Brunel., J. M. (2010). New insights into the antibacterial mechanism of action of squalamine. *Journal of Antimicrobial Chemotherapy*, 65(8), 1688–1693. <https://doi.org/10.1093/jac/dkq213>
- American Society for Microbiology. (2005). *Manual of antimicrobial susceptibility testing*. *Manual of antimicrobial susceptibility testing*. <https://doi.org/10.1007/s13398-014-0173-7.2>
- Angeles., D. M., and Scheffers., D. (2021). The Cell Wall of *Bacillus subtilis*, 539–596.
- Appelbaum., P. C. (2007). Microbiology of Antibiotic Resistance in *Staphylococcus aureus*. *Clinical Infectious Diseases*, 45(Supplement 3), S165–S170. <https://doi.org/10.1086/519474>
- Archer., N., Mazaitis., M., and Costerton., J. (2011). *Staphylococcus aureus* biofilms: properties, regulation, and roles in human disease. ..., 2(5), 445–459. <https://doi.org/10.4161/viru.2.5.17724>
- Armbruster., C. R., Wolter., D. J., Mishra., M., Hayden., H. S., Radey., M. C., Merrihew., G., Maccoss., M. J., Burns., J., Wozniak., D. J., Parsek., M. R., and Hoffman., R. (2016). *Staphylococcus aureus* Protein A Mediates Interspecies Interactions at the Cell Surface of *Pseudomonas aeruginosa*, 7(3), 1–9. <https://doi.org/10.1128/mBio.00538-16>.Editor

- Bandow., J. E., Brötz., H., Ole., L. I., Labischinski., H., Hecker., M., Bro., H., Ingo., L., and Leichert., O. (2003). Proteomic Approach to Understanding Antibiotic Action. *Antimicrobial Agents and Chemotherapy*, 47(3), 948–955. <https://doi.org/10.1128/AAC.47.3.948>
- Beaudoin., T., Kennedy., S., Yau., Y., and Waters., V. (2016). Visualizing the Effects of Sputum on Biofilm Development Using a Chambered Coverglass Model. *Journal of Visualized Experiments*, (118), 2–7. <https://doi.org/10.3791/54819>
- Beckingsale., T. (2008). *Staphylococcus aureus : salt stress , cell wall de ciencia , and Biofilm formation Staphylococcus aureus : Salt Stress , Cell Wan Deficiency , and Biofilm Formation* . Durham University. Retrieved from [http://etheses.dur.ac.uk/2513/1/2513\\_525.pdf](http://etheses.dur.ac.uk/2513/1/2513_525.pdf)
- Beenken., K. E., Dunman., P. M., Mcaleese., F., Macapagal., D., Murphy., E., Projan., S. J., Blevins., J. S., and Smeltzer., M. S. (2004). Global Gene Expression in *Staphylococcus aureus* Biofilms, 186(14), 4665–4684. <https://doi.org/10.1128/JB.186.14.4665>
- Belley., A., Neesham-grenon., E., Arhin., F. F., Mckay., G. A., Parr., T. R., and Moeck., G. (2008). Assessment by Time-Kill Methodology of the Synergistic Effects of Oritavancin in Combination with Other Antimicrobial Agents against *Staphylococcus aureus* □, 52(10), 3820–3822. <https://doi.org/10.1128/AAC.00361-08>
- Benson., T. E., Harris., M. S., Choi., G. H., Cialdella., J. I., Herberg., J. T., Martin., J. P., and Baldwin., E. T. (2001). A Structural Variation for MurB : X-ray Crystal Structure of *Staphylococcus aureus*, 2340–2350.
- Bérdy., J. (2012). Thoughts and facts about antibiotics: Where we are now and where we are heading. *Journal of Antibiotics*, 65(8), 385–395. <https://doi.org/10.1038/ja.2012.27>
- Beveridge., T. J. (1999). Structures of gram-negative cell walls and their derived membrane vesicles. *Journal of Bacteriology*, 181(16), 4725–4733. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/10438737>
- Beveridge., T. J., and Graham., L. L. (1991). Surface layers of bacteria. *Microbiological Reviews*, 55(4), 684–705. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/1723487>
- Bharti., S. K., and Singh., S. K. (2009). Metal Based Drugs : Current Use and Future Potential. *Library*, 1(2), 39–51.



- Bimanand., L., Taherikalani., M., Jalilian., F. A., Sadeghifard., N., Ghafourian., S., Mahdavi., Z., Mohamadi., S., Sayehmiri., K., Hematian., A., and Pakzad., I. (2018). Association between biofilm production, adhesion genes and drugs resistance in different SCCmec types of methicillin resistant *Staphylococcus aureus* strains isolated from several major hospitals of Iran. *Iranian Journal of Basic Medical Sciences*, 21(4), 400–403. <https://doi.org/10.22038/ijbms.2018.19378.5132>
- Bochner., B. R. (2003a). New technologies to assess genotype-phenotype relationships. *Nature Reviews Genetics*, 4(4), 309–314. <https://doi.org/10.1038/nrg1046>
- Bochner., B. R. (2003b). New technologies to assess genotype-phenotype relationships. *Nature Reviews Genetics*, 4(4), 309–314. <https://doi.org/10.1038/nrg1046>
- Bochner., B. R., Gadzinski., P., and Panomitros., E. (2001). Phenotype Microarrays for high-throughput phenotypic testing and assay of gene function. *Genome Research*, 11(7), 1246–1255. <https://doi.org/10.1101/gr.186501>
- Boswihi., S. S., and Udo., E. E. (2018). Methicillin-resistant *Staphylococcus aureus* : An update on the epidemiology, treatment options and infection control. *Current Medicine Research and Practice*, 8(1), 18–24. <https://doi.org/10.1016/j.cmrp.2018.01.001>
- Bourne., C. R., Wakeham., N., Bunce., R. A., Nammalwar., B., Darrell Berlin., K., and Barrow., W. W. (2012). Classifying compound mechanism of action for linking whole cell phenotypes to molecular targets. *Journal of Molecular Recognition*, 25(4), 216–223. <https://doi.org/10.1002/jmr.2174>
- Brambilla., L. Z. S., Endo., E. H., Cortez., D. A. G., and Dias Filho., B. P. (2017). Anti-biofilm activity against *Staphylococcus aureus* MRSA and MSSA of neolignans and extract of *Piper regnellii*. *Revista Brasileira de Farmacognosia*, 27(1), 112–117. <https://doi.org/10.1016/J.BJP.2016.08.008>
- Cabral., M. P., García., P., Beceiro., A., Rumbo., C., Pérez., A., Moscoso., M., and Bou., G. (2017). Design of live attenuated bacterial vaccines based on D-glutamate auxotrophy. *Nature Communications*, 8(May). <https://doi.org/10.1038/ncomms15480>
- Carneiro., C. R. W., Postol., E., Nomizo., R., Reis., L. F. L., and Brentani., R. R. (2004). Identification of enolase as a laminin-binding protein on the surface of *Staphylococcus aureus*, 6, 604–608. <https://doi.org/10.1016/j.micinf.2004.02.003>
- Carr., H., Wlodkowski., J., Rosenkranz., H., Carr., S., Wlodkowski., T., and Rosenkranz., H. (1973). Silver Sulfadiazine: In vitro antibacterial activity. *Antimicrobial Agents and Chemotherapy*, 4, 585–587.
- Castro., W., Navarro., M., and Biot., C. (2013). Medicinal potential of ciprofloxacin and its derivatives. *Future Medicinal Chemistry*, 5(1), 81–96. <https://doi.org/10.4155/fmc.12.181>

- Chang., E. L., Simmers., C., and Knight., D. A. (2010). Cobalt complexes as antiviral and antibacterial agents. *Pharmaceuticals*, 3(6), 1711–1728. <https://doi.org/10.3390/ph3061711>
- Chen., B. J., Jamaludin., N. S., Khoo., C. H., See., T. H., Sim., J. H., Cheah., Y. K., Halim., S. N. A., Seng., H. L., and Tiekink., E. R. T. (2016). In vitro antibacterial and time kill evaluation of mononuclear phosphane-gold(I) dithiocarbamates. *Journal of Inorganic Biochemistry*, 163, 68–80. <https://doi.org/10.1016/j.jinorgbio.2016.08.002>
- Chohan., Z. H., Supuran., C. T., and Scozzafava., A. (2005). Metal binding and antibacterial activity of ciprofloxacin complexes, 20(3), 303–307. <https://doi.org/10.1080/14756360310001624948>
- Choo., E. J., and Chambers., H. F. (2016). Treatment of Methicillin-Resistant *Staphylococcus aureus* Bacteremia, 48(4), 267–273.
- Chou., T. (2010). Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method, 70(2), 440–447. <https://doi.org/10.1158/0008-5472.CAN-09-1947>
- Chudobova., D., Cihalova., K., Dostalova., S., Ruttkay-Nedecky., B., Merlos Rodrigo., M. A., Tmejova., K., Kopel., P., Nejd., L., Kudr., J., Gumulec., J., Krizkova., S., Kynicky., J., Kizek., R., and Adam., V. (2014). Comparison of the effects of silver phosphate and selenium nanoparticles on *Staphylococcus aureus* growth reveals potential for selenium particles to prevent infection. *FEMS Microbiology Letters*, 351(2), 195–201. <https://doi.org/10.1111/1574-6968.12353>
- Cihalova., K., Chudobova., D., Michalek., P., Moulick., A., Guran., R., Kopel., P., Adam., V., Kizek., R., Cihalova., K., Chudobova., D., Michalek., P., Moulick., A., Guran., R., Kopel., P., Adam., V., and Kizek., R. (2015). *Staphylococcus aureus* and MRSA Growth and Biofilm Formation after Treatment with Antibiotics and SeNPs. *International Journal of Molecular Sciences*, 16(10), 24656–24672. <https://doi.org/10.3390/ijms161024656>
- Coelho., L. R., Souza., R. R., Ferreira-carvalho., B. T., Sa., A. M., Sa., A. M., and Janeiro., R. De. (2017). agr RNAIII divergently regulates glucose-induced biofilm formation in clinical isolates of *Staphylococcus aureus*, (2008), 3480–3490. <https://doi.org/10.1099/mic.0.2007/016014-0>
- Costerton., J. W. (2012). Bacterial Biofilms : A Common Cause of Persistent Infections, 1318(1999). <https://doi.org/10.1126/science.284.5418.1318>
- Cramariuc., O., Rog., T., Javanainen., M., Monticelli., L., Polishchuk., A. V., and Vatulainen., I. (2012). Mechanism for translocation of fluoroquinolones across lipid membranes. *Biochimica et Biophysica Acta - Biomembranes*, 1818(11), 2563–2571. <https://doi.org/10.1016/j.bbamem.2012.05.027>

- Cucarella., C., Solano., C., Valle., J., Amorena., B., Lasa., I. G. O., and Penade., R. (2001). Bap , a Staphylococcus aureus Surface Protein Involved in Biofilm Formation, *183*(9), 2888–2896. <https://doi.org/10.1128/JB.183.9.2888>
- Dakheel., K. H., Abdul Rahim., R., Neela., V. K., Al-Obaidi., J. R., Hun., T. G., and Yusoff., K. (2016). Methicillin-Resistant Staphylococcus aureus Biofilms and Their Influence on Bacterial Adhesion and Cohesion. *BioMed Research International*, 2016. <https://doi.org/10.1155/2016/4708425>
- de Kievit., T. R., and Iglewski., B. H. (2000). MINIREVIEW Bacterial Quorum Sensing in Pathogenic Relationships, *68*(9), 4839–4849.
- Deresinski., S. (2009). Vancomycin in combination with other antibiotics for the treatment of serious methicillin-resistant staphylococcus aureus infections. *Clinical Infectious Diseases*, *49*(7), 1072–1079. <https://doi.org/10.1086/605572>
- Di Veroli., G. Y., Fornari., C., Wang., D., Mollard., S., Bramhall., J. L., Richards., F. M., and Jodrell., D. I. (2016). Combenefit: An interactive platform for the analysis and visualization of drug combinations. *Bioinformatics*, *32*(18), 2866–2868. <https://doi.org/10.1093/bioinformatics/btw230>
- Dobinsky., S., Kiel., K., Rohde., H., Bartscht., K., Knobloch., J. K., Horstkotte., M. A., and Mack., D. (2003). Glucose-Related Dissociation between icaADBC Transcription and Biofilm Expression by Staphylococcus epidermidis : Evidence for an Additional Factor Required for Polysaccharide Intercellular Adhesin Synthesis, *185*(9), 2879–2886. <https://doi.org/10.1128/JB.185.9.2879>
- Doern., C. D. (2014). When does 2 plus 2 equal 5? A review of antimicrobial synergy testing. *Journal of Clinical Microbiology*, *52*(12), 4124–4128. <https://doi.org/10.1128/JCM.01121-14>
- Doublet., P., Van Heijenoort., J., Bohin., J. P., and Mengin-Lecreulx., D. (1993). The murI gene of Escherichia coli is an essential gene that encodes a glutamate racemase activity. *Journal of Bacteriology*, *175*(10), 2970–2979. <https://doi.org/10.1128/jb.175.10.2970-2979.1993>
- Downer., R., Roche., F., Park., P. W., Mecham., R. P., and Foster., T. J. (2002). The Elastin-binding Protein of Staphylococcus aureus ( EbpS ) Is Expressed at the Cell Surface as an Integral Membrane Protein and Not as a Cell Wall-associated Protein \*. *The Journal of Biological Chemistry*, *277*(1), 243–250. <https://doi.org/10.1074/jbc.M107621200>
- Drago., L., De Vecchi., E., Nicola., L., and Gismondo., M. R. (2007). In vitro evaluation of antibiotics' combinations for empirical therapy of suspected methicillin resistant Staphylococcus aureus severe respiratory infections. *BMC Infectious Diseases*, *7*, 1–7. <https://doi.org/10.1186/1471-2334-7-111>
- El-Azizi., M. (2016). Novel Microdilution Method to Assess Double and Triple Antibiotic Combination Therapy in Vitro. *International Journal of Microbiology*, 2016. <https://doi.org/10.1155/2016/4612021>

- El Zoeiby., A., Sanschagrín., F., and Levesque., R. C. (2003). Structure and function of the Mur enzymes: Development of novel inhibitors. *Molecular Microbiology*, 47(1), 1–12. <https://doi.org/10.1046/j.1365-2958.2003.03289.x>
- Elkashif., A., and Seleem., M. N. (2020). Investigation of auranofin and gold-containing analogues antibacterial activity against multidrug-resistant *Neisseria gonorrhoeae*. *Scientific Reports*, 10(1), 1–9. <https://doi.org/10.1038/s41598-020-62696-3>
- Elsome., A. M., Hamilton-Miller., J. M. . T., Brumfitt., W., and Noble., W. C. (1996). Antimicrobial activities in vitro and in vivo of transition element complexes containing gold (I) and osmium (VI). *Journal of Antimicrobial Chemotherapy*, 37, 911–918. Retrieved from <http://jac.oxfordjournals.org/>
- Elsome., A. M., Hamilton-miller., J. M. T., Bmmfitt., W., and Noble., W. C. (1996). Antimicrobial activities in vitro and in vivo of transition element complexes containing gold ( I ) and osmium ( VI ), 911–918.
- Farrel., N. (1989). *Transition Metal Complexes as Drugs and Chemotherapeutic Agents*. *Biochemical Education* (Vol. 18). [https://doi.org/10.1016/0307-4412\(90\)90247-L](https://doi.org/10.1016/0307-4412(90)90247-L)
- Fayyaz., M., Mirza., I. A., Ahmed., Z., Abbasi., S. A., Hussain., A., and Ali., S. (2013). In vitro susceptibility of chloramphenicol against methicillin-resistant *Staphylococcus aureus*. *Journal of the College of Physicians and Surgeons--Pakistan : JCPSP*, 23(9), 637–640. <https://doi.org/09.2013/JCPSP.637640>
- Ferrer., M. D., Rodriguez., J. C., Álvarez., L., Artacho., A., Royo., G., and Mira., A. (2017). Effect of antibiotics on biofilm inhibition and induction measured by real-time cell analysis. *Journal of Applied Microbiology*, 122(3), 640–650. <https://doi.org/10.1111/jam.13368>
- Fillat., M. F., Gimeno., M. C., Laguna., A., Latorre., E., Ortego., L., and Villacampa., M. D. (2011). Synthesis , Structure and Bactericide Activity of ( Aminophosphane ) gold ( I ) Thiolate Complexes, (I), 1487–1495. <https://doi.org/10.1002/ejic.201001195>
- Finberg., R. W., Moellering., R. C., Tally., F. P., Craig., W. A., Pankey., G. A., Dellinger., E. P., West., M. A., Joshi., M., Linden., P. K., Rolston., K. V., Rotschafer., J. C., and Rybak., M. J. (2004). The Importance of Bactericidal Drugs : Future Directions in Infectious Disease, 01655.
- Fisher., S. L. (2008). Glutamate racemase as a target for drug discovery. *Microbial Biotechnology*, 1(5), 345–360. <https://doi.org/10.1111/j.1751-7915.2008.00031.x>
- Foster., T. J., Savolainen., K., Paulin., L., Korhonen., T. K., and Kuusela., P. (2001). Expression of pls , a Gene Closely Associated with the mecA Gene of Methicillin-Resistant *Staphylococcus aureus* , Prevents Bacterial Adhesion In Vitro, 69(5), 3013–3020. <https://doi.org/10.1128/IAI.69.5.3013>

- Fouquier., J., and Guedj., M. (2015, June 1). Analysis of drug combinations: current methodological landscape. *Pharmacology Research and Perspectives*. Wiley-Blackwell Publishing Ltd. <https://doi.org/10.1002/prp2.149>
- Fowles., C. C., Smoak., E. M., and Banerjee., I. A. (2010). Interactions of zeatin with gold ions and biomimetic formation of gold complexes and nanoparticles. *Colloids and Surfaces B: Biointerfaces*, 78(2), 250–258. <https://doi.org/10.1016/j.colsurfb.2010.03.010>
- Francius., G., Domenech., O., Mingeot-Leclercq., M. P., and Dufrêne., Y. F. (2008). Direct observation of *Staphylococcus aureus* cell wall digestion by lysostaphin. *Journal of Bacteriology*, 190(24), 7904–7909. <https://doi.org/10.1128/JB.01116-08>
- Frei., A. (2020). Metal complexes, an untapped source of antibiotic potential? *Antibiotics*, 9(2). <https://doi.org/10.3390/antibiotics9020090>
- French., G. L. (2006). Bactericidal agents in the treatment of MRSA infections - The potential role of daptomycin. *Journal of Antimicrobial Chemotherapy*, 58(6), 1107–1117. <https://doi.org/10.1093/jac/dkl393>
- Fricker., S. P. (1996). *Medical Uses of Gold Compounds: Past, Present and Future*. Retrieved from <https://link.springer.com/content/pdf/10.1007%2F978-1-4020-1546-4.pdf>
- Fridkin., S. K. (2001). Vancomycin-Intermediate and -Resistant *Staphylococcus aureus*: What the Infectious Disease Specialist Needs to Know, 30333.
- Frieden., T. (2013). *Antibiotic resistance threats in the United States*. Centers for Disease Control and Prevention. <https://doi.org/http://dx.doi.org/10.15620/cdc:82532>. U.S.
- Garrett., T. R., Bhakoo., M., and Zhang., Z. (2008). Bacterial adhesion and biofilms on surfaces. *Progress in Natural Science*, 18(9), 1049–1056. <https://doi.org/10.1016/j.pnsc.2008.04.001>
- Garza-Cervantes., J. A., Chávez-Reyes., A., Castillo., E. C., García-Rivas., G., Ortega-Rivera., O. A., Salinas., E., Ortiz-Martínez., M., Gómez-Flores., S. L., Peña-Martínez., J. A., Pepi-Molina., A., Treviño-González., M. T., Zarate., X., Cantú-Cárdenas., M. E., Escarcega-Gonzalez., C. E., and Morones-Ramírez., J. R. (2017). Synergistic antimicrobial effects of silver/transition-metal combinatorial treatments. *Scientific Reports*, 7(1), 1–16. <https://doi.org/10.1038/s41598-017-01017-7>
- George P. Tegos and Michael R. Hamblin. (2005). Disruptive innovations: new anti-infectives in the age of resistance. *Biophysical Chemistry*, 257(5), 2432–2437. <https://doi.org/10.1016/j.immuni.2010.12.017>. Two-stage



- Gerits, E., Blommaert, E., Lippell, A., O'Neill, A. J., Weytjens, B., De Maeyer, D., Fierro, A. C., Marchal, K., Marchand, A., Chaltin, P., Spincemaille, P., De Brucker, K., Thevissen, K., Cammue, B. P. A., Swings, T., Liebens, V., Fauvart, M., Verstraeten, N., and Michiels, J. (2016). Elucidation of the mode of action of a new antibacterial compound active against *Staphylococcus aureus* and *Pseudomonas aeruginosa*. *PLoS ONE*, *11*(5), 1–17. <https://doi.org/10.1371/journal.pone.0155139>
- Gli., B. Đ., and Djuran., M. I. (2014). overview of different biological activities in relation to the oxidation state of the gold ion and the ligand structure, 5950–5969. <https://doi.org/10.1039/c4dt00022f>
- Glisic., B. D., and Djuran., M. I. (2014). Gold complexes as antimicrobial agents: an overview of different biological activities in relation to the oxidation state of the gold ion and Glisic, B. D., & Djuran, M. I. (2014). Gold complexes as antimicrobial agents: an overview of different biological. *Dalton Transactions*, *43*(16), 5950–5969. <https://doi.org/10.1039/C4DT00022F>
- Glišić., B. Đ., and Djuran., M. I. (2014). Gold complexes as antimicrobial agents: an overview of different biological activities in relation to the oxidation state of the gold ion and the ligand structure. *Dalton Trans.*, *43*(16), 5950–5969. <https://doi.org/10.1039/C4DT00022F>
- Gowrishankar., S., Kamaladevi., A., Balamurugan., K., and Pandian., S. K. (2016). In Vitro and in Vivo Biofilm Characterization of Methicillin-Resistant *Staphylococcus aureus* from Patients Associated with Pharyngitis Infection. *BioMed Research International*, 2016. <https://doi.org/10.1155/2016/1289157>
- Grace., A. N., and Pandian., K. (2008). Quinolone Antibiotic-Capped Gold Nanoparticles and Their Antibacterial Efficacy Against Gram Positive and Gram Negative Organisms. *Journal of Bionanoscience*, *1*(2), 96–105. <https://doi.org/10.1166/jbns.2007.018>
- Grein., F., Müller., A., Scherer., K. M., Liu., X., Ludwig., K. C., Klöckner., A., Strach., M., Sahl., H., Kubitscheck., U., and Schneider., T. (2020). T. Ca<sup>2+</sup>-Daptomycin targets cell wall biosynthesis by forming a tripartite complex with undecaprenyl-coupled intermediates and membrane lipids. *Nature Communications*, (2020), 1–11. <https://doi.org/10.1038/s41467-020-15257-1>
- Gross., M., Cramton., S. E., Götz., F., and Peschel., A. (2001). Key Role of Teichoic Acid Net Charge in *Staphylococcus aureus* Colonization of Artificial Surfaces Key Role of Teichoic Acid Net Charge in *Staphylococcus aureus* Colonization of Artificial Surfaces. *Infection and Immunity*, *69*(5), 3423–2426. <https://doi.org/10.1128/IAI.69.5.3423>
- Gu., Y. G., Florjancic., A. S., Clark., R. F., Zhang., T., Cooper., C. S., Anderson., D. D., Lerner., C. G., Mccall., J. O., Cai., Y., Black-schaefer., C. L., Stamper., G. F., Hajduk., P. J., and Beutel., B. A. (2004). Structure – activity relationships of novel potent MurF inhibitors, *14*, 267–270. <https://doi.org/10.1016/j.bmcl.2003.09.073>

- Guerra., W., de Andrade Azevedo., E., de Souza Monteiro., A. R., Bucciarelli-Rodriguez., M., Chartone-Souza., E., Nascimento., A. M. A., Fontes., A. P. S., Le Moyec., L., and Pereira-Maia., E. C. (2005). Synthesis, characterization, and antibacterial activity of three palladium(II) complexes of tetracyclines. *Journal of Inorganic Biochemistry*, *99*(12), 2348–2354. <https://doi.org/10.1016/J.JINORGBIO.2005.09.001>
- Gutiérrez., D., Fernández., L., Martínez., B., Ruas-Madiedo., P., García., P., and Rodríguez., A. (2017). Real-Time Assessment of *Staphylococcus aureus* Biofilm Disruption by Phage-Derived Proteins. *Frontiers in Microbiology*, *8*, 1632. <https://doi.org/10.3389/fmicb.2017.01632>
- Gutiérrez., D., Hidalgo-Cantabrana., C., Rodríguez., A., García., P., and Ruas-Madiedo., P. (2016). Monitoring in Real Time the Formation and Removal of Biofilms from Clinical Related Pathogens Using an Impedance-Based Technology. *PLOS ONE*, *11*(10), e0163966. <https://doi.org/10.1371/journal.pone.0163966>
- Hafidh., R. R., Abdulmir., A. S., and Abu Bakar., F. (2012). Phenotype microarray profiling of the antibacterial activity of red cabbage. *Functional Foods in Health and Disease*, *2*(6), 212–227.
- Harbut., M. B., Vilchèze., C., Luo., X., Hensler., M. E., Guo., H., Yang., B., Chatterjee., A. K., Nizet., V., Jacobs., W. R., Schultz., P. G., and Wang., F. (2015). Auranofoin exerts broad-spectrum bactericidal activities by targeting thiol-redox homeostasis. *Proceedings of the National Academy of Sciences*, *112*(14), 4453–4458. <https://doi.org/10.1073/pnas.1504022112>
- Harris., L. G., Foster., S. J., Richards., R. G., Lambert., P., Stickler., D., and Eley., A. (2002). An introduction to *Staphylococcus aureus*, and techniques for identifying and quantifying *S. aureus* adhesins in relation to adhesion to biomaterials: Review. *European Cells and Materials*, *4*, 39–60. <https://doi.org/10.22203/eCM.v004a04>
- Hibbitts., A., and O’Leary., C. (2018). Emerging nanomedicine therapies to counter the rise of Methicillin-resistant *Staphylococcus aureus*. *Materials*, *11*(2). <https://doi.org/10.3390/ma11020321>
- Hiramatsu., K., Kayayama., Y., Matsuo., M., Aiba., Y., Saito., M., Hishinuma., T., and Iwamoto., A. (2014). Vancomycin-intermediate resistance in *Staphylococcus aureus*. *Integrative Medicine Research*, *2*(4), 213–224. <https://doi.org/10.1016/j.jgar.2014.04.006>
- Hobman., J. L., and Crossman., L. C. (2015). Bacterial antimicrobial metal ion resistance. *Journal of Medical Microbiology*, *64*(2014), 471–497. <https://doi.org/10.1099/jmm.0.023036-0>
- Hoerr., V., Duggan., G. E., Zbytnuik., L., Poon., K. K. H., Große., C., Neugebauer., U., Methling., K., Löffler., B., and Vogel., H. J. (2016). Characterization and prediction of the mechanism of action of antibiotics through NMR metabolomics. *BMC Microbiology*, *16*(1), 1–14. <https://doi.org/10.1186/s12866-016-0696-5>

- Hu., Y., Chen., L., Ha., S., Gross., B., Falcone., B., Walker., D., Mokhtarzadeh., M., and Walker., S. (2003). Crystal structure of the MurG : UDP-GlcNAc complex reveals common structural principles of a superfamily of glycosyltransferases, *100*(3), 845–849.
- Hwang., I. -s., Hwang., J. H., Choi., H., Kim., K.-J., and Lee., D. G. (2012). Synergistic effects between silver nanoparticles and antibiotics and the mechanisms involved. *Journal of Medical Microbiology*, *61*(Pt\_12), 1719–1726. <https://doi.org/10.1099/jmm.0.047100-0>
- IAGC. (2019). *No Time to Wait: Securing The Future From Drug-Resistant Infection*. World Health Organization (Vol. 54). Retrieved from <https://www.who.int/antimicrobial-resistance/interagency-coordination-group/final-report/en/>
- Ing Yeo., C., and Tiekink., E. R. (2020). Crystal structure of ( $\mu$ 2-1,1'-bis(diphenylphosphino)hexane- $\kappa$ 2P,P')-bis [(Z)-N-(3-fluorophenyl)-O-methylthiocarbamato- $\kappa$ S]digold(I), C<sub>46</sub>H<sub>46</sub>Au<sub>2</sub>F<sub>2</sub>N<sub>2</sub>O<sub>2</sub>P<sub>2</sub>S<sub>2</sub>. *Z. Kristallogr. NCS*, *1*(ahead-of-print), aop. <https://doi.org/10.1515/ncrs-2020-0354>
- Ito., T., Hiramatsu., K., Oliveira., D. C., De Lencastre., H., Zhang., K., Westh., H., O'Brien., F., Giffard., P. M., Coleman., D., Tenover., F. C., Boyle-Vavra., S., Skov., R. L., Enright., M. C., Kreiswirth., B., Kwan., S. K., Grundmann., H., Laurent., F., Sollid., J. E., Kearns., A. M., Goering., R., John., J. F., Daum., R., and Soderquist., B. (2009). Classification of staphylococcal cassette chromosome mec (SCCmec): Guidelines for reporting novel SCCmec elements. *Antimicrobial Agents and Chemotherapy*, *53*(12), 4961–4967. <https://doi.org/10.1128/AAC.00579-09>
- Iwata., Y., Satou., K., Furuichi., K., and Yoneda., I. (2020). International Journal of Infectious Diseases Collagen adhesion gene is associated with bloodstream infections caused by methicillin-resistant Staphylococcus aureus. *International Journal of Infectious Diseases*, *91*, 22–31. <https://doi.org/10.1016/j.ijid.2019.11.003>
- Jacobsen., J. S., Joyner., D. C., Borglin., S. E., Hazen., T. C., Arkin., A. P., and Bethel., E. W. (n.d.). Visualization of Growth Curve Data from Phenotype Microarray Experiments Earth Sciences Division , Lawrence Berkeley National Laboratory , Physical Biosciences Division , Lawrence Berkeley National Laboratory , Virtual Institute for Microbial Stress and S.
- Ji., Y., Yin., D., Fox., B., Holmes., D. J., Payne., D., and Rosenberg., M. (2004). Validation of antibacterial mechanism of action using regulated antisense RNA expression in Staphylococcus aureus. *FEMS Microbiology Letters*, *231*(2), 177–184. [https://doi.org/10.1016/S0378-1097\(03\)00931-5](https://doi.org/10.1016/S0378-1097(03)00931-5)



- Jindal., H. M., Zandi., K., Ong., K. C., Velayuthan., R. D., Rasid., S. M., Samudi Raju., C., and Sekaran., S. D. (2017). Mechanisms of action and *in vivo* antibacterial efficacy assessment of five novel hybrid peptides derived from Indolicidin and Ranalexin against *Streptococcus pneumoniae*. *PeerJ*, 5, e3887. <https://doi.org/10.7717/peerj.3887>
- Jürgens., S., and Casini., A. (2017). Mechanistic Insights into Gold Organometallic Compounds and their Biomedical Applications. *CHIMIA International Journal for Chemistry*, 71(3), 92–101. <https://doi.org/10.2533/chimia.2017.92>
- Konaté., K., Mavoungou., J. F., Lepengué., A. N., Aworet-Samseny., R. R., Hilou., A., Souza., A., Dicko., M. H., and M'batchi., B. (2012). Antibacterial activity against  $\beta$ -lactamase producing Methicillin and Ampicillin-resistant Staphylococcus aureus: fractional Inhibitory Concentration Index (FICI) determination. *PeerJ*, 11, 1. <https://doi.org/10.1186/1476-0711-11-18>
- Kong., E. F., Tsui., C., and Kucharřková., S. (2017). cross Modulation of Staphylococcus aureus Candida albicans Quorum Sensing.
- Kot., B., Sytykiewicz., H., and Sprawka., I. (2018). Expression of the Biofilm-Associated Genes in Methicillin-Resistant Staphylococcus aureus in Biofilm and Planktonic Conditions. *International Journal of Molecular Sciences Article*. <https://doi.org/10.3390/ijms19113487>
- Kumar., R. S., and Arunachalam., S. (2008). Synthesis, micellar properties, DNA binding and antimicrobial studies of some surfactant–cobalt(III) complexes. *Biophysical Chemistry*, 136(2–3), 136–144. <https://doi.org/10.1016/J.BPC.2008.05.007>
- Laddomada., F., Miyachiro., M. M., Jessop., M., Patin., D., Job., V., Mengin-lecreulx., D., Roy., A. Le, Ebel., C., Breyton., C., Gutsche., I., and Dessen., A. (2019). The MurG glycosyltransferase provides an oligomeric scaffold for the cytoplasmic steps of peptidoglycan biosynthesis in the human pathogen Bordetella pertussis, (November 2018), 1–17. <https://doi.org/10.1038/s41598-019-40966-z>
- Lade., H., and Kim., J. (2021). Bacterial Targets of Antibiotics in Methicillin-Resistant Staphylococcus aureus.
- Leite., G. C. (2015). Effect of Antibiotics Combination and Comparison of Methods for Detection of Synergism in Multiresistant Gram-Negative Bacteria. *Journal of Infectious Diseases and Therapy*, 03(02). <https://doi.org/10.4172/2332-0877.1000207>
- Lemire., J. a, Harrison., J. J., and Turner., R. J. (2013). Antimicrobial activity of metals: mechanisms, molecular targets and applications. *Nature Reviews. Microbiology*, 11(6), 371–384. <https://doi.org/10.1038/nrmicro3028>
- Levison., M. E. (2004). Pharmacodynamics of antimicrobial drugs, 18, 451–465. <https://doi.org/10.1016/j.idc.2004.04.012>

- Lien., L. T. Q. (2018). *ANTIBIOTIC RESISTANCE : IMPLICATIONS OF HOSPITAL PRACTICES FOR PUBLIC HEALTH A study from Hanoi , Vietnam La Thi Quynh Lien From the Department of Public Health Sciences HOSPITAL PRACTICES FOR PUBLIC HEALTH A study from Hanoi , Vietnam.* Karolinska Institutet. Retrieved from <https://openarchive.ki.se/xmlui/handle/10616/46214>
- Liu., H., Ritter., T. K., Sadamoto., R., Sears., P. S., and Wu., M. (2003). Acceptor Specificity and Inhibition of the Bacterial Cell-Wall Glycosyltransferase MurG, *92037*, 603–609. <https://doi.org/10.1002/cbic.200300557>
- Liu., Y., and Breukink., E. (2016). The Membrane Steps of Bacterial Cell Wall Synthesis as Antibiotic Targets. <https://doi.org/10.3390/antibiotics5030028>
- Lorian., V. (1971). The Mode of Action of Antibiotics on Gram-Negative Bacilli. *Archives of Internal Medicine*, *128*(4), 623–632. <https://doi.org/10.1001/archinte.1971.00310220131022>
- Lundqvist., T., Fisher., S. L., Kern., G., Folmer., R. H. A., Xue., Y., Newton., D. T., Keating., T. A., Alm., R. A., and De Jonge., B. L. M. (2007). Exploitation of structural and regulatory diversity in glutamate racemases. *Nature*, *447*(7146), 817–822. <https://doi.org/10.1038/nature05689>
- Lynch., A. S., and Abbanat., D. (2010). New antibiotic agents and approaches to treat biofilm-associated infections, 1373–1387.
- Man., N. Y. T., Knight., D. R., Stewart., S. G., Mckinley., A. J., Riley., T. V., and Hammer., K. A. (2018). Spectrum of antibacterial activity and mode of action of a novel tris- stilbene bacteriostatic compound. *Scientific Reports*, 1–9. <https://doi.org/10.1038/s41598-018-25080-w>
- Mann., P. A., Müller., A., Xiao., L., Pereira., P. M., Yang., C., Lee., S. H., Trzeciak., J., Schneeweis., J., Moreira., M., She., X., Gill., C., Balibar., C. J., Labroli., M., Su., J., Flattery., A., Sherborne., B., Maier., R., Tan., C. M., Black., T., Önder., K., Monsma., F. J., Pinho., M. G., Schneider., T., and Roemer., T. (2013). Murgocil is a Highly Bioactive Staphylococcal-specific Inhibitor of the Peptidoglycan Glycosyltransferase Enzyme MurG. <https://doi.org/10.1021/cb400487f>
- Manna., A. C., and Cheung., A. L. (2006). Expression of SarX , a Negative Regulator of agr and Exoprotein Synthesis , Is Activated by MgrA in Staphylococcus aureus †, *188*(12), 4288–4299. <https://doi.org/10.1128/JB.00297-06>
- Manner., S., Goeres., D. M., Skogman., M., Vuorela., P., and Fallarero., A. (2017). Prevention of Staphylococcus aureus biofilm formation by antibiotics in 96-Microtiter Well Plates and Drip Flow Reactors: critical factors influencing outcomes. *Scientific Reports*, *7*, 43854. <https://doi.org/10.1038/srep43854>
- Martens., E., and Demain., A. L. (2017). The antibiotic resistance crisis, with a focus on the United States. *Journal of Antibiotics*, *70*(5), 520–526. <https://doi.org/10.1038/ja.2017.30>

- McCarthy., H., Rudkin., J. K., Black., N. S., Gallagher., L., O'neill., E., O'gara., J. P., Geoghegan., J. A., and Otto., M. (2015). Methicillin resistance and the biofilm phenotype in *Staphylococcus aureus*. <https://doi.org/10.3389/fcimb.2015.00001>
- McGuinness., W. A., Malachowa., N., and DeLeo., F. R. (2017). Vancomycin resistance in *Staphylococcus aureus*. *The Yale Journal of Biology and Medicine*, 90(2), 269–281.
- McPhillie., M. J., Cain., R. M., Narramore., S., Fishwick., C. W. G., and Simmons., K. J. (2015). Computational Methods to Identify New Antibacterial Targets. *Chemical Biology & Drug Design*, 85(1), 22–29. <https://doi.org/10.1111/cbdd.12385>
- Mei., M. L., Li., Q. L., Chu., C. H., Lo., E. C. M., and Samaranayake., L. P. (2013). Antibacterial effects of silver diamine fluoride on multi-species cariogenic biofilm on caries. *Annals of Clinical Microbiology and Antimicrobials*, 12(1), 1–7. <https://doi.org/10.1186/1476-0711-12-4>
- Merino., N., Toledo-arana., A., Vergara-irigaray., M., Valle., J., Solano., C., Calvo., E., Lopez., J. A., Foster., T. J., and Penade., R. (2009). Protein A-Mediated Multicellular Behavior in *Staphylococcus aureus* □, 191(3), 832–843. <https://doi.org/10.1128/JB.01222-08>
- Merritt., J. H. (2015). growing and analyzing static Biofilm, 1–29. <https://doi.org/10.1002/9780471729259.mc01b01s00.Growing>
- Mesak., L. R., and Davies., J. (2009). Phenotypic changes in ciprofloxacin-resistant *Staphylococcus aureus*. *Research in Microbiology*. <https://doi.org/10.1016/j.resmic.2009.09.013>
- Miragaia., M. (2018). Factors Contributing to the Evolution of *mecA* -Mediated  $\beta$  -lactam Resistance in *Staphylococci*: Update and New Insights From Whole Genome Sequencing ( WGS ), 9(November), 1–16. <https://doi.org/10.3389/fmicb.2018.02723>
- Mishra., A., Kaushik., N. K., Verma., A. K., and Gupta., R. (2008). Synthesis, characterization and antibacterial activity of cobalt(III) complexes with pyridine–amide ligands. *European Journal of Medicinal Chemistry*, 43(10), 2189–2196. <https://doi.org/10.1016/J.EJMECH.2007.08.015>
- Mizdal., C. R., Stefanello., S. T., da Costa Flores., V., Agertt., V. A., Bonez., P. C., Rossi., G. G., da Silva., T. C., Antunes Soares., F. A., de Lourenço Marques., L., and de Campos., M. M. A. (2018). The antibacterial and anti-biofilm activity of gold-complexed sulfonamides against methicillin-resistant *Staphylococcus aureus*. *Microbial Pathogenesis*, 123, 440–448. <https://doi.org/10.1016/j.micpath.2018.08.002>

- Mizdal., C. R., Stefanello., S. T., Nogara., P. A., Antunes Soares., F. A., de Lourenço Marques., L., and de Campos., M. M. A. (2018). Molecular docking, and anti-biofilm activity of gold-complexed sulfonamides on *Pseudomonas aeruginosa*. *Microbial Pathogenesis*, 125, 393–400. <https://doi.org/10.1016/j.micpath.2018.10.004>
- Monecke., S., Jatzwauk., L., Müller., E., Nitschke., H., Pfohl., K., Slickers., P., Reissig., A., Ruppelt-Lorz., A., and Ehricht., R. (2016). Diversity of SCCmec Elements in *Staphylococcus aureus* as Observed in South-Eastern Germany. *PLOS ONE*, 11(9), e0162654. <https://doi.org/10.1371/journal.pone.0162654>
- Moormeier., D. E., and Bayles., K. W. (2017). *Staphylococcus aureus* biofilm: a complex developmental organism. *Molecular Microbiology*, 104(3), 365–376. <https://doi.org/10.1111/mmi.13634>
- Mueller., M., Pen., A. De, and Derendorf., H. (2004). MINIREVIEW Issues in Pharmacokinetics and Pharmacodynamics of Anti-Infective Agents : Kill Curves versus MIC, 48(2), 369–377. <https://doi.org/10.1128/AAC.48.2.369>
- Navid., A. (2012). *Microbial Systems Biology*. Springer. <https://doi.org/10.1007/978-1-61779-827-6>
- Nazari., Z. E., Banoee., M., Sepahi., A. A., Rafii., F., and Shahverdi., A. R. (2012). The combination effects of trivalent gold ions and gold nanoparticles with different antibiotics against resistant *Pseudomonas aeruginosa*, 53–59. <https://doi.org/10.1007/s13404-012-0048-7>
- Nira Rabin., Y. Z., Opoku-Temeng., C., Yixuan Du., E. B., and Sintim., & H. O. (2015). Biofilm formation mechanisms and targets for developing antibiofilm agents, 8, 697–711.
- Novelli., F., Recine., M., Sparatore., F., and Juliano., C. (1999). Gold ( I ) complexes as antimicrobial agents, 54, 232–236.
- O.I.E. (2012). Laboratory Methodologies for Bacterial Antimicrobial Susceptibility Testing. *OIE Terrestrial Manual*, 1–11. <https://doi.org/10.4065/mcp.2010.0639>
- O’Neill., E., Pozzi., C., Houston., P., Smyth., D., Humphreys., H., Robinson., D. A., Gara., J. P. O., and Icrobiol., J. C. L. I. N. M. (2007). Association between Methicillin Susceptibility and Biofilm Regulation in *Staphylococcus aureus* Isolates from Device-Related Infections □ †, 45(5), 1379–1388. <https://doi.org/10.1128/JCM.02280-06>
- O’Toole., G. A. (2011). Microtiter dish biofilm formation assay. *Journal of Visualized Experiments : JoVE*, (47). <https://doi.org/10.3791/2437>
- Odds., F. C. (2003). Synergy, antagonism, and what the chequerboard puts between them. *Journal of Antimicrobial Chemotherapy*, 52(1), 1–1. <https://doi.org/10.1093/jac/dkg301>

- Oehninger., L., Rubbiani., R., and Ott., I. (2013). N-Heterocyclic carbene metal complexes in medicinal chemistry. *Dalton Transactions*, 42(10), 3269–3284. <https://doi.org/10.1039/C2DT32617E>
- Oliva., B., O’Neill., A. J., Miller., K., Stubbings., W., and Chopra., I. (2004). Anti-staphylococcal activity and mode of action of clofazimine. *Journal of Antimicrobial Chemotherapy*, 53(3), 435–440. <https://doi.org/10.1093/jac/dkh114>
- Ortego., L., Gonzalo-asensio., J., Laguna., A., Villacampa., M. D., and Gimeno., M. C. (2015). (Aminophosphane) gold (I) and silver (I) complexes as antibacterial agents. *Journal of Inorganic Biochemistry*, 146, 19–27. <https://doi.org/10.1016/j.jinorgbio.2015.01.007>
- Ortego., L., Gonzalo-Asensio., J., Laguna., A., Villacampa., M. D., and Gimeno., M. C. (2015). (Aminophosphane)gold(I) and silver(I) complexes as antibacterial agents. *Journal of Inorganic Biochemistry*, 146, 19–27. <https://doi.org/10.1016/j.jinorgbio.2015.01.007>
- Owings., J. P., McNair., N. N., Mui., Y. F., Gustafsson., T. N., Holmgren., A., Contel., M., Goldberg., J. B., and Mead., J. R. (2016). Auranofin and N-heterocyclic carbene gold-analogs are potent inhibitors of the bacteria *Helicobacter pylori*. *FEMS Microbiology Letters*, 363(14), 1–6. <https://doi.org/10.1093/femsle/fnw148>
- Özdemir., İ., Temelli., N., Günal., S., and Demir., S. (2010). Gold(I) Complexes of N-Heterocyclic Carbene Ligands Containing Benzimidazole: Synthesis and Antimicrobial Activity. *Molecules*. <https://doi.org/10.3390/molecules15042203>
- Pankey., G. A., and Sabath., L. D. (2004a). Clinical Relevance of Bacteriostatic versus Bactericidal Mechanisms of Action in the Treatment of Gram-Positive Bacterial Infections. *Clinical Infectious Diseases*, 38(6), 864–870. <https://doi.org/10.1086/381972>
- Pankey., G. A., and Sabath., L. D. (2004b). Clinical Relevance of Bacteriostatic versus Bactericidal Mechanisms of Action in the Treatment of Gram-Positive Bacterial Infections. *Clinical Infectious Diseases*, 38(6), 864–870. <https://doi.org/10.1086/381972>
- Pawar., A., Jha., P., Chopra., M., Chaudhry., U., and Saluja., D. (2020). Screening of natural compounds that targets glutamate racemase of *Mycobacterium tuberculosis* reveals the anti-tubercular potential of flavonoids. *Scientific Reports*, 10(1), 1–12. <https://doi.org/10.1038/s41598-020-57658-8>
- Peach., K. C., Bray., W. M., Winslow., D., Linington., P. F., and Linington., R. G. (2013). Mechanism of action-based classification of antibiotics using high-content bacterial image analysis. *Molecular BioSystems*, 9(7), 1837. <https://doi.org/10.1039/c3mb70027e>
- Petersen., P. J., Jones., C. H., and Bradford., P. A. (2007). In vitro antibacterial activities of tigecycline and comparative agents by time-kill kinetic studies in fresh Mueller-Hinton broth, 59, 347–349. <https://doi.org/10.1016/j.diagmicrobio.2007.05.013>



- Petrelli., D., Repetto., A., Ercole., S. D., Rombini., S., Ripa., S., Prenna., M., and Vitali., L. A. (2017). Analysis of meticillin-susceptible and meticillin- resistant biofilm-forming *Staphylococcus aureus* from catheter infections isolated in a large Italian hospital, (2008), 364–372. <https://doi.org/10.1099/jmm.0.47621-0>
- Pietiäinen., M., François., P., Hyryläinen., H., Tangomo., M., Sass., V., Sahl., H., Schrenzel., J., and Kontinen., V. P. (2009). Transcriptome analysis of the responses of *Staphylococcus aureus* to antimicrobial peptides and characterization of the roles of *vraDE* and *vraSR* in antimicrobial resistance, 15. <https://doi.org/10.1186/1471-2164-10-429>
- Pozo., J. L., and Patel., R. (2007). The Challenge of Treating Biofilm-associated Bacterial Infections, 82(2). <https://doi.org/10.1038/sj.clpt.6100247>
- Pradeep Kumar., M., Tejaswi., S., Rambabu., A., Kalalbandi., V. K. A., and Shivaraj. (2015). Synthesis, crystal structure, DNA binding and cleavage studies of copper(II) complexes with isoxazole Schiff bases. *Polyhedron*, 102, 111–120. <https://doi.org/10.1016/J.POLY.2015.07.052>
- Rani., N., Kumar., C., Arunachalam., A., and Ptv., L. (2018). Rutin as a potential inhibitor to target peptidoglycan pathway of *Staphylococcus aureus* cell wall synthesis, 3(3), 1–9. <https://doi.org/10.15761/CMID.1000142>
- Redgrave., L. S., Sutton., S. B., Webber., M. A., and Piddock., L. J. V. (2014). Fluoroquinolone resistance: Mechanisms, impact on bacteria, and role in evolutionary success. *Trends in Microbiology*, 22(8), 438–445. <https://doi.org/10.1016/j.tim.2014.04.007>
- Resch., A., Rosenstein., R., Nerz., C., Go., F., and Icrobiol., A. P. P. L. E. N. M. (2005). Differential Gene Expression Profiling of *Staphylococcus aureus* Cultivated under Biofilm and Planktonic Conditions, 71(5), 2663–2676. <https://doi.org/10.1128/AEM.71.5.2663>
- Rizzotto., M. (2012). Metal Complexes as Antimicrobial Agents. In *A Search for Antibacterial Agents*. <https://doi.org/10.5772/45651>
- Rodvold., K. A., and Mcconeghy., K. W. (2014). Methicillin-resistant staphylococcus aureus therapy: Past, present, and future. *Clinical Infectious Diseases*, 58(SUPPL. 1), 20–27. <https://doi.org/10.1093/cid/cit614>
- Rojas., R., Bustamante., B., Bauer., J., Fernández., I., Albán., J., and Lock., O. (2003). Antimicrobial activity of selected Peruvian medicinal plants. *Journal of Ethnopharmacology*, 88(2–3), 199–204. [https://doi.org/10.1016/S0378-8741\(03\)00212-5](https://doi.org/10.1016/S0378-8741(03)00212-5)
- Roymahapatra., G., M. Mandal., S., F. Porto., W., Samanta., T., Giri., S., Dinda., J., L. Franco., O., and K. Chattaraj., P. (2012). Pyrazine Functionalized Ag(I) and Au(I)-NHC Complexes are Potential Antibacterial Agents. *Current Medicinal Chemistry*, 19(24), 4184–4193. <https://doi.org/10.2174/092986712802430090>

- Sabounchei., S. J., Pourshahbaz., M., Hashemi., A., Ahmadi., M., Karamian., R., Asadbegy., M., and Khavasi., H. R. (2014). Synthesis and structural characterization of dimeric phosphine ylide Cu(I) complexes: Application in Suzuki cross-coupling reactions and biological evaluation as antibacterial agents. *Journal of Organometallic Chemistry*, 761, 111–119. <https://doi.org/10.1016/j.jorganchem.2014.03.017>
- Sabounchei., S. J., Shahriary., P., Salehzadeh., S., Gholiee., Y., Nematollahi., D., Chehregani., A., and Amani., A. (2014). Gold(iii) complexes of 5-methyl-5-(pyridyl)-2,4-imidazolidenedione: Synthesis, physicochemical, theoretical, antibacterial, and cytotoxicity investigation. *New Journal of Chemistry*, 38(3), 1199–1210. <https://doi.org/10.1039/c3nj01042b>
- Santiago., C. (2015). *Santiago , Carolina ( 2015 ) Application of plant metabolites to overcome antibiotic resistance of methicillin resistant Staphylococcus aureus ( MRSA )*. PhD thesis , University of Nottingham . Nottingham. Retrieved from Santiago., C. (2015). Santiago , Carolina ( 2015 ) Application of plant metabolites to overcome antibiotic resistance of methicillin resistant Staphylococcus aureus ( MRSA ). PhD thesis , University of Nottingham . Nottingham.
- Sauer., J., Bachman., M. A., and Swanson., M. S. (2005). The phagosomal transporter A couples threonine acquisition to differentiation and replication of Legionella pneumophila in macrophages.
- Savić., N. D., Milivojević., D. R., Glišić., B. Đ., Ilic-Tomic., T., Veselinovic., J., Pavić., A., Vasiljević., B., Nikodinovic-Runic., J., and Djuran., M. I. (2016a). A comparative antimicrobial and toxicological study of gold( iii ) and silver( i ) complexes with aromatic nitrogen-containing heterocycles: synergistic activity and improved selectivity index of Au( iii )/Ag( i ) complexes mixture. *RSC Advances*, 6(16), 13193–13206. <https://doi.org/10.1039/C5RA26002G>
- Savić., N. D., Milivojević., D. R., Glišić., B. Đ., Ilic-Tomic., T., Veselinovic., J., Pavić., A., Vasiljević., B., Nikodinovic-Runic., J., and Djuran., M. I. (2016b). A comparative antimicrobial and toxicological study of gold( iii ) and silver( i ) complexes with aromatic nitrogen-containing heterocycles: synergistic activity and improved selectivity index of Au( iii )/Ag( i ) complexes mixture. *RSC Advances*, 6(16), 13193–13206. <https://doi.org/10.1039/C5RA26002G>
- Schenone., M., Dančik., V., Wagner., B. K., and Clemons., P. A. (2013). Target identification and mechanism of action in chemical biology and drug discovery. *Nature Chemical Biology*, 9(4), 232–240. <https://doi.org/10.1038/nchembio.1199>
- Schillaci., D., Arizza., V., Dayton., T., Camarda., L., and Stefano., V. Di. (2008). In vitro anti-biofilm activity of Boswellia spp . oleogum resin essential oils, 47, 433–438. <https://doi.org/10.1111/j.1472-765X.2008.02469.x>
- Schwalbe., R., Steele-Moore., L., and Goodwin., A. C. (2007a). *Antimicrobial Susceptibility testing procols*.

- Schwalbe., R., Steele-Moore., L., and Goodwin., A. C. (2007b). *Antimicrobial Susceptibility Testing Protocols. Journal of Chemical Information and Modeling* (Vol. 53). <https://doi.org/10.1017/CBO9781107415324.004>
- Selvaganapathy., M., and Raman., N. (2016). Pharmacological Activity of a Few Transition Metal Complexes: A Short Review. *Journal of Chemical Biology & Therapeutics*, 01(02), 1–17. <https://doi.org/10.4172/2572-0406.1000108>
- Selvaraj., V., Nirmala Grace., A., Alagar., M., and Hamerton., I. (2010). Antimicrobial and anticancer efficacy of antineoplastic agent capped gold nanoparticles. *Journal of Biomedical Nanotechnology*, 6(2), 129–137. <https://doi.org/10.1166/jbn.2010.1115>
- Senn., M. M., Mccallum., N., and Berger-b., B. (2010). International Journal of Medical Microbiology Regulation of antibiotic resistance in Staphylococcus aureus, 300, 118–129. <https://doi.org/10.1016/j.ijmm.2009.08.015>
- Shaku., M., Ealand., C., Matlhabe., O., Lala., R., and Kana., B. D. (2020). *Peptidoglycan biosynthesis and remodeling revisited. Advances in Applied Microbiology* (1st ed., Vol. 112). Elsevier Inc. <https://doi.org/10.1016/bs.aamsb.2020.04.001>
- She., P., Liu., Y., Wang., Y., Tan., F., Luo., Z., and Wu., Y. (2019). Antibiofilm efficacy of the gold compound auranofin on dual species biofilms of Staphylococcus aureus and Candida sp. *Journal of Applied Microbiology*, 128(1), 88–101. <https://doi.org/10.1111/jam.14443>
- She., P., Zhou., L., Li., S., Liu., Y., Xu., L., Chen., L., Luo., Z., and Wu., Y. (2019). Synergistic Microbicidal Effect of Auranofin and Antibiotics Against Planktonic and Biofilm-Encased S. aureus and E. faecalis. *Frontiers in Microbiology*, 10(OCT), 2453. <https://doi.org/10.3389/fmicb.2019.02453>
- Shukla., S. K., and Rao., T. S. (2013). Dispersal of Bap-mediated Staphylococcus aureus biofilm by proteinase K. *The Journal of Antibiotics*, (August 2012), 55–60. <https://doi.org/10.1038/ja.2012.98>
- Siddiqui., A. H., and Koirala., J. (2020). Methicillin Resistant Staphylococcus Aureus. StatPearls. Retrieved from <https://www.ncbi.nlm.nih.gov/books/NBK482221/>
- Sim., J., Jamaludin., N. S., Khoo., C., Cheah., Y., Nadiah., S., Abdul., B., and Seng., H. (2014). In vitro antibacterial and time-kill evaluation of phosphane-gold ( I ) dithiocarbamates , R 3 PAu [ S 2 CN ( iPr ) CH 2 CH 2 OH ] for R = Ph , Cy and Et , against a broad range of Gram-positive and Gram-negative bacteria, 225–236. <https://doi.org/10.1007/s13404-014-0144-y>
- Singh., Naorem, Peter., U., Goswami., G., and Fekete., C. (2020). Characterization of methicillin - resistant Staphylococcus aureus through genomics approach. 3 *Biotech*, 10(9), 1–19. <https://doi.org/10.1007/s13205-020-02387-y>



- Singh., Nina, and Yeh., P. J. (2017). antibiotic resistance, 70(11), 1033–1042. <https://doi.org/10.1038/ja.2017.102.Suppressive>
- Sobral., R. G., Ludovice., A. M., De Lencastre., H., and Tomasz., A. (2006). Role of murF in cell wall biosynthesis: Isolation and characterization of a murF conditional mutant of *Staphylococcus aureus*. *Journal of Bacteriology*, 188(7), 2543–2553. <https://doi.org/10.1128/JB.188.7.2543-2553.2006>
- Sobral., Rita G., Jones., A. E., Des Etages., S. G., Dougherty., T. J., Peitzsch., R. M., Gaasterland., T., Ludovice., A. M., De Lencastre., H., and Tomasz., A. (2007). Extensive and genome-wide changes in the transcription profile of *Staphylococcus aureus* induced by modulating the transcription of the cell wall synthesis gene murF. *Journal of Bacteriology*, 189(6), 2376–2391. <https://doi.org/10.1128/JB.01439-06>
- Sochacki., K. A., Barns., K. J., Bucki., R., and Weisshaar., J. C. (2011). Real-time attack on single *Escherichia coli* cells by the human antimicrobial peptide LL-37. <https://doi.org/10.1073/pnas.1101130108>
- Song., T., Duperthuy., M., and Wai., S. N. (2016). Sub-Optimal Treatment of Bacterial Biofilms. *Antibiotics (Basel, Switzerland)*, 5(2). <https://doi.org/10.3390/antibiotics5020023>
- Sreedharan., S. M., and Singh., R. (2019). Ciprofloxacin functionalized biogenic gold nanoflowers as nanoantibiotics against pathogenic bacterial strains. *International Journal of Nanomedicine*, 14, 9905–9916. <https://doi.org/10.2147/IJN.S224488>
- Stewart., P. S., and Costerton., J. W. (2001). Antibiotic resistance of bacteria in biofilms. *THE LANCET*, 358, 135–138.
- Stick., R. V, and Williams., S. J. (2009). *Carbohydrates : The Essential Molecules of Life* (Second). Elsevier.
- Su., P. W., Yang., C. H., Yang., J. F., Su., P. Y., and Chuang., L. Y. (2015). Antibacterial activities and antibacterial mechanism of *Polygonum cuspidatum* extracts against nosocomial drug-resistant pathogens. *Molecules*, 20(6), 11119–11130. <https://doi.org/10.3390/molecules200611119>
- Sy., C. L., Huang., T.-S., Chen., C. S., Chen., Y.-S., Tsai., H.-C., Wann., S.-R., Wu., K.-S., Chen., J.-K., Lee., S. S.-J., and Liu., Y.-C. (2015). Synergy of beta-lactams with vancomycin against methicillin-resistant *Staphylococcus aureus* : correlation of the disk diffusion and the checkerboard methods. *Journal of Clinical Microbiology*, 54(December), JCM.01779-15. <https://doi.org/10.1128/JCM.01779-15>
- Tallarida., R. J. (2006). An Overview of Drug Combination Analysis with Isobolograms. *Journal of Pharmacology and Experimental Therapeutics*, 319(1), 1–7. <https://doi.org/10.1124/jpet.106.104117>

- Tam., V. H., Schilling., A. N., and Nikolaou., M. (2005). Modelling time – kill studies to discern the pharmacodynamics of meropenem, (March), 699–706. <https://doi.org/10.1093/jac/dki086>
- Tan., Y. J., Tan., Y. S., Yeo., C. I., Chew., J., and Tiekink., E. R. T. (2019). In vitro antibacterial and time kill evaluation of binuclear tricyclohexylphosphanesilver(I) dithiocarbamates, {Cy3PAg(S2CNRR')}<sub>2</sub>. *Journal of Inorganic Biochemistry*, 192(September 2018), 107–118. <https://doi.org/10.1016/j.jinorgbio.2018.12.017>
- Teitzel., G. M., and Parsek., M. R. (2003). Heavy metal resistance of biofilm and planktonic *Pseudomonas aeruginosa*. *Appl. Environ. Microbiol.*, 69(4), 2313–2320. <https://doi.org/10.1128/AEM.69.4.2313>
- Tella, AC and Obaleye., J. (2009). Copper(II) Complexes of 4, 4-Diaminodiphenylsulphone: Synthesis, Characterization and Biological Studies. *Journal of Chemistry*.
- Thangamani., S., Mohammad., H., Abushahba., M. F. N., Sobreira., T. J. P., Hedrick., V. E., Paul., L. N., and Seleem., M. N. (2016). Antibacterial activity and mechanism of action of auranofin against multi-drug resistant bacterial pathogens. *Scientific Reports*, 6(1), 22571. <https://doi.org/10.1038/srep22571>
- Thangamani., S., Younis., W., and Seleem., M. N. (2015). Repurposing ebselen for treatment of multidrug-resistant staphylococcal infections. *Scientific Reports*, 5(1), 11596. <https://doi.org/10.1038/srep11596>
- Theuretzbacher., U. (2011). Resistance drives antibacterial drug development. *Current Opinion in Pharmacology*, 11(5), 433–438. <https://doi.org/10.1016/j.coph.2011.07.008>
- Tiekink., E. R. T. (2002). Gold derivatives for the treatment of cancer, 42, 225–248.
- Tortora., G. J., Funke., B. R., and Case., C. L. (2018). *Microbiology: An Introduction* (13th ed.). Boston: Pearson Education.
- Tremaroli., V., Fedi., S., Turner., R. J., Ceri., H., and Zannoni., D. (2008). *Pseudomonas pseudoalcaligenes* KF707 upon biofilm formation on a polystyrene surface acquire a strong antibiotic resistance with minor changes in their tolerance to metal cations and metalloid oxyanions. *Archives of Microbiology*. <https://doi.org/10.1007/s00203-008-0360-z>
- Vaidya., M. Y., McBain., A. J., Butler., J. A., Banks., C. E., and Whitehead., K. A. (2017). Antimicrobial Efficacy and Synergy of Metal Ions against *Enterococcus faecium*, *Klebsiella pneumoniae* and *Acinetobacter baumannii* in Planktonic and Biofilm Phenotypes. *Scientific Reports*, 7(1), 1–9. <https://doi.org/10.1038/s41598-017-05976-9>
- Valle., J., Toledo-arana., A., Ghigo., J., Amorena., B., Penadés., J. R., and Lasa., I. (2003). SarA and not s B is essential for biofilm development by *Staphylococcus aureus*, 48, 1075–1087.

- van Duuren., J. B. J. H., Müsken., M., Karge., B., Tomasch., J., Wittmann., C., Häussler., S., and Brönstrup., M. (2017). Use of Single-Frequency Impedance Spectroscopy to Characterize the Growth Dynamics of Biofilm Formation in *Pseudomonas aeruginosa*. *Scientific Reports*, 7(1), 5223. <https://doi.org/10.1038/s41598-017-05273-5>
- Van Vuuren., S. F., Suliman., S., and Viljoen., A. M. (2009). The antimicrobial activity of four commercial essential oils in combination with conventional antimicrobials. *Letters in Applied Microbiology*, 48(4), 440–446. <https://doi.org/10.1111/j.1472-765X.2008.02548.x>
- Vergalli., J., Dumont., E., Cinquin., B., Maigre., L., Pajovic., J., Bacqué., E., Mourez., M., Réfrégiers., M., and Pagès., J. M. (2017). Fluoroquinolone structure and translocation flux across bacterial membrane. *Scientific Reports*, 7(1), 1–8. <https://doi.org/10.1038/s41598-017-08775-4>
- Vincent., I. M., Ehmann., D. E., Mills., S. D., Perros., M., and Barrett., M. P. (2016). Untargeted metabolomics to ascertain antibiotic modes of action. *Antimicrobial Agents and Chemotherapy*, 60(4), 2281–2291. <https://doi.org/10.1128/AAC.02109-15>
- Von Eiff., C., McNamara., P., Becker., K., Bates., D., Lei., X. H., Ziman., M., Bochner., B. R., Peters., G., and Proctor., R. A. (2006). Phenotype microarray profiling of *Staphylococcus aureus* menD and hemB mutants with the small-colony-variant phenotype. *Journal of Bacteriology*, 188(2), 687–693. <https://doi.org/10.1128/JB.188.2.687-693.2006>
- Walsh., C. (2003). *Antibiotics: Actions, origins, resistance*.
- Weaver., L., Noyce., J. O., Michels., H. T., and Keevil., C. W. (2010). Potential action of copper surfaces on meticillin-resistant *Staphylococcus aureus*. *Journal of Applied Microbiology*, 109(6), 2200–2205. <https://doi.org/10.1111/j.1365-2672.2010.04852.x>
- Worthing., K. A., Schwendener., S., Perreten., V., Saputra., S., and Coombs., G. W. (2018). Characterization of *Staphylococcal* Cassette Chromosome *mec* pseudintermedius Infections in Australian Animals, 3(6), 1–7.
- Yang., Y., Severin., A., Chopra., R., Krishnamurthy., G., Singh., G., Hu., W., Keeney., D., Svenson., K., Petersen., P. J., Labthavikul., P., Shlaes., D. M., Rasmussen., B. A., Failli., A. A., Shumsky., J. S., Kutterer., K. M. K., Gilbert., A., and Mansour., T. S. (2006). 3, 5-Dioxopyrazolidines, Novel Inhibitors of UDP-N-Acetylenolpyruvylglucosamine Reductase (MurB) with Activity against Gram-Positive Bacteria, 50(2), 556–564. <https://doi.org/10.1128/AAC.50.2.556>
- Yeo., C. I., Tan., S. L., Kwong., H. C., Edward., R. T., Yeo., C. I., Tan., S. L., Kwong., H. C., and Tiekink., E. R. T. (2020). [(Z)-N-(3-Fluorophenyl)-O-methylthiocarbamate-κS](tri-phenylphosphane-κP)gold(I): crystal structure, Hirshfeld surface analysis and computational study, (I), 1284–1290.

- Yeo., C. I., Tan., Y. S., and Tiekink., E. R. T. (2020a). Crystal structure of (tricyclohexylphosphane- $\kappa$ P) - [(Z) - N - (3-fluorophenyl) - O - methylthiocarbamate- $\kappa$ 1S] gold (I), C<sub>26</sub>H<sub>40</sub>AuFNOPS, (I), 1–5.
- Yeo., C. I., Tan., Y. S., and Tiekink., E. R. T. (2020b). Crystal structure of ( $\mu$ 2-1,1'-bis(diphenylphosphino)ferrocene- $\kappa$ 2P,P')-bis[(Z)N-(3-fluorophenyl)-O-methylthiocarbamate-S]digold(I) chloroform solvate, C<sub>50</sub>H<sub>42</sub>Au<sub>2</sub>F<sub>2</sub>FeN<sub>2</sub>O<sub>2</sub>P<sub>2</sub>S<sub>2</sub>, CHCl<sub>3</sub>. *Zeitschrift Für Kristallographie - New Crystal Structures*, 0(0), aop. <https://doi.org/10.1515/ncrs-2020-0386>
- Yeo., C. I., and Tiekink., E. R. T. (2020). Crystal structure of ( $\mu$ 2-1,1'-bis(diphenylphosphino)butane- $\kappa$ 2P,P')-bis[(Z)-N-(3-fluorophenyl)-O-methylthiocarbamate- $\kappa$ S]-di-gold(I), C<sub>44</sub>H<sub>42</sub>Au<sub>2</sub>F<sub>2</sub>N<sub>2</sub>O<sub>2</sub>P<sub>2</sub>S<sub>2</sub>. *Zeitschrift Für Kristallographie - New Crystal Structures*, 0(0), aop. <https://doi.org/10.1515/ncrs-2020-0353>
- Zhang., Jianying, Liu., J., Ling., J., Tong., Z., Fu., Y., and Liang., M. (2016). Inactivation of glutamate racemase (MurI) eliminates virulence in *Streptococcus mutans*. *Microbiological Research*, 186–187, 1–8. <https://doi.org/10.1016/j.micres.2016.02.003>
- Zhang., Jiaqin, and Biswas., I. (2009). A Phenotypic microarray analysis of *Streptococcus mutans* liaS mutant, 155(Pt 1), 61–68. <https://doi.org/10.1099/mic.0.023077-0.A>
- Zhang., Ling, Fan., F., Palmer., L. M., Lonetto., M. A., Petit., C., Voelker., L. L., John., A. S., Bankosky., B., Rosenberg., M., and Mcdevitt., D. (2000). Regulated gene expression in *Staphylococcus aureus* for identifying conditional lethal phenotypes and antibiotic mode of action, 255, 297–305.
- Zhang., Lixin. (2005). Integrated approaches for discovering novel drugs from microbial natural products. *Natural Products: Drug Discovery and Therapeutic Medicine*, (6), 33–55. [https://doi.org/10.1007/978-1-59259-976-9\\_2](https://doi.org/10.1007/978-1-59259-976-9_2)